ActiveCare (ACARQ) 10-K 13 Jan 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Sep. 30, 2016	Jan. 12, 2017	Mar. 31, 2016
Document and Entity Information:
Entity Registrant Name	ACTIVECARE, INC.
Document Type	10-K
Document Period End Date	Sep. 30, 2016
Trading Symbol	acar
Amendment Flag	false
Entity Central Index Key	1,429,896
Current Fiscal Year End Date	--09-30
Entity Common Stock, Shares Outstanding		115,112,802
Entity Public Float			$ 6,257,680
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	No
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Current assets:
Cash	$ 167,737	$ 172,436
Accounts receivable, net	487,001	936,866
Inventory	204,736	742,471
Prepaid expenses and other	644,857	523,561
Total current assets	1,504,331	2,375,334
Property and equipment, net	86,734	135,770
Deposits and other assets	17,846	17,846
Domain name, net	9,295	10,010
Total assets	1,618,206	2,538,960
Current liabilities:
Accounts payable	1,700,448	4,493,211
Accounts payable, related party	291,753	162,797
Accrued expenses	2,101,711	743,967
Current portion of notes payable	3,722,899	1,259,916
Current portion of notes payable, related party	3,898,124	492,495
Dividends payable	606,545	567,350
Derivatives liability	2,054,071	79,347
Total current liabilities	14,375,551	7,799,083
Notes payable, net of current portion	7,353,856
Notes payable, related party, net of current portion		3,348,251
Total liabilities	21,729,407	11,147,334
Stockholders' deficit:
Preferred stock, $.00001 par value: 10,000,000 shares authorized; 45,000 sharesof Series D; 70,070 shares of Series E; and 0 and 5,361 shares of Series F outstanding, respectively	1	1
Common stock, $.00001 par value: 200,000,000 shares authorized; 115,112,802 and 78,113,971 shares outstanding, respectively	1,151	781
Additional paid-in capital, common and preferred	88,066,261	83,231,002
Accumulated deficit	(108,178,614)	(91,840,158)
Total stockholders' deficit	(20,111,201)	(8,608,374)
Total liabilities and stockholders' deficit	$ 1,618,206	$ 2,538,960

Consolidated Balance Sheets Par

Consolidated Balance Sheets Parenthetical - $ / shares	Sep. 30, 2016	Sep. 30, 2015
Consolidated Balance Sheets Parenthetical
Preferred stock par value	$ 0.00001	$ 0.00001
Preferred stock shares authorized	10,000,000	10,000,000
Preferred stock shares outstanding	120,431	120,431
Common stock par value	$ 0.00001	$ 0.00001
Common stock shares authorized	200,000,000	200,000,000
Common stock shares outstanding	115,112,802	78,113,971

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Revenues:
Chronic illness monitoring supplies revenues	$ 6,327,832	$ 5,994,793
Chronic illness monitoring fee revenues	1,136,314	603,188
Total Chronic illness monitoring revenues	7,464,146	6,597,981
Cost of revenues:
Chronic illness monitoring supplies cost of revenues	4,876,321	4,669,470
Chronic illness monitoring fee cost of revenues	457,851	527,357
Total Chronic illness monitoring cost of revenues	5,334,172	5,196,827
Gross profit	2,129,974	1,401,154
Operating expenses:
Selling, general and administrative (including $3,306,047 and $5,762,755, respectively, of stock-based compensation)	8,194,678	10,358,410
Research and development	248,441	106,526
Total operating expenses	8,443,119	10,464,936
Loss from operations	(6,313,145)	(9,063,782)
Other income (expense):
Gain on derivatives liability	3,405,035	128,942
Gain on liability settlements	297,067	260,830
Gain on lease termination		91,692
Impairment of goodwill		(825,894)
Other income (expense)	(2,618)	14,129
Loss on disposal of property and equipment	(2,780)	(42,336)
Loss on induced conversion of debt	(379,132)
Interest expense, net	(2,963,747)	(977,234)
Loss on extinguishment of debt	(3,163,240)	(927,784)
Total other expense	(2,809,415)	(2,277,655)
Loss from continuing operations	(9,122,560)	(11,341,437)
Loss from discontinued operations		(186,232)
Net loss	(9,122,560)	(11,527,669)
Deemed dividends on redemption of preferred stock	(6,484,236)
Dividends on preferred stock	(731,660)	(994,983)
Deemed dividends on conversion of accrued dividends to common stock		(301,097)
Net loss attributable to common stockholders	$ (16,338,456)	$ (12,823,749)
Net loss per common share - basic
Continuing operations - basic	$ (0.17)	$ (0.25)
Discontinued operations - basic	0	0
Net loss per common share - basic	(0.17)	(0.25)
Net loss per common share - diluted
Continuing operations - diluted	(0.19)	(0.25)
Discontinued operations - diluted	0	0
Net loss per common share - diluted	$ (0.19)	$ (0.25)
Weighted average common shares outstanding - basic	96,669,000	51,444,000
Weighted average common shares outstanding - diluted	98,047,503	51,444,000

Consolidated Statements of Ope5

Consolidated Statements of Operations Parenthetical - USD ($)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Consolidated Statements of Operations Parenthetical
Compensation expense paid in stock or amortization of stock options and warrants	$ 3,306,047	$ 5,762,755

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficit - USD ($)	Series D Preferred Stock	Series E Preferred Stock	Series F Preferred Stock	Common stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Sep. 30, 2014		$ 1		$ 458	$ 73,183,429	$ (78,327,447)	$ (5,143,559)
Balance - shares at Sep. 30, 2014	45,000	70,070	5,361	45,815,351
Issuance of common stock for services				$ 220	4,088,675		4,088,895
Issuance of common stock for services - shares				22,047,659
Issuance of common stock for finance fees				$ 5	89,392		89,397
Issuance of common stock for finance fees - shares				509,976
Issuance of common stock for loan origination fee				$ 63	1,129,937		1,130,000
Issuance of common stock for loan origination fee - shares				6,250,000
Issuance of common stock for dividends and related interest				$ 35	975,433	(301,097)	674,371
Issuance of common stock for dividends and related interest - shares				3,490,985
Stock based compensation					3,032,304		3,032,304
Issuance of options for services					42,870		42,870
Amortization of Series F preferred stock as dividends					688,962	(688,962)
Net loss						(11,527,669)	(11,527,669)
Dividends on preferred stock						(994,983)	(994,983)
Balance at Sep. 30, 2015		$ 1		$ 781	83,231,002	(91,840,158)	(8,608,374)
Balance - shares at Sep. 30, 2015	45,000	70,070	5,361	78,113,971
Issuance of common stock for services				$ 29	274,134		274,163
Issuance of common stock for services - shares				2,858,047
Issuance of common stock for finance fees				$ 14	135,954		135,968
Issuance of common stock for finance fees - shares				1,396,866
Issuance of common stock for loan origination fee				$ 23	194,817		194,840
Issuance of common stock for loan origination fee - shares				2,276,000
Redemption of preferred stock for common stock, debt and reissuance of warrants				$ 100	(2,555,463)	(6,484,236)	(9,039,599)
Redemption of preferred stock for common stock, debt and reissuance of warrants - shares			(5,361)	10,000,000
Issuance of common stock for dividends and related interest				$ 3	18,614		18,617
Issuance of common stock for dividends and related interest - shares				302,517
Issuance of common stock for debt conversions				$ 201	1,666,509		1,666,710
Issuance of common stock for debt conversions - shares				20,165,401
Stock based compensation					2,556,810		2,556,810
Issuance of options for services					130,246		130,246
Beneficial conversion features on debt					2,413,638		2,413,638
Net loss						(9,122,560)	(9,122,560)
Dividends on preferred stock						(731,660)	(731,660)
Balance at Sep. 30, 2016		$ 1		$ 1,151	$ 88,066,261	$ (108,178,614)	$ (20,111,201)
Balance - shares at Sep. 30, 2016	45,000	70,070		115,112,802

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities:
Net loss	$ (9,122,560)	$ (11,527,669)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on extinguishment of debt	3,163,240	927,784
Stock-based compensation expense	2,819,298	4,864,864
Amortization of debt discounts	743,940
Stock and warrants issued for interest expense	728,732	647,679
Stock and warrants issued for services	486,749	897,891
Loss on induced conversion of debt	379,132
Depreciation and amortization	51,376	290,700
Loss on disposal of property and equipment	2,780	42,336
Impairment of goodwill		825,894
Gain on lease termination		(91,692)
Gain on liability settlements	(297,067)	(260,830)
Gain on derivatives liability	(3,405,035)	(128,942)
Changes in operating assets and liabilities:
Change in accounts receivable	379,519	698,794
Change in inventory	537,735	906,849
Change in prepaid expenses and other	(586,965)	20,400
Change in accounts payable	66,322	892,170
Change in accrued liabilities	1,311,216	215,054
Net cash used in operating activities	(2,741,588)	(778,718)
Cash flows from investing activities:
Proceeds from sale of property and equipment	600	938
Proceeds from sale of discontinued operations		478,738
Purchases of property and equipment	(5,004)	(15,289)
Net cash used in investing activities	(4,404)	464,387
Cash flows from financing activities:
Proceeds from issuance of notes payable, net	6,544,287	1,262,490
Proceeds from issuance of related-party notes payable, net	250,000
Proceeds from issuance of warrants in connection with notes payable	2,967
Principal payments on related-party notes payable	(13,943)	(15,000)
Principal payments on notes payable	(4,042,018)	(957,750)
Net cash provided by financing activities	2,741,293	289,740
Net decrease in cash	(4,699)	(24,591)
Cash, beginning of the year	172,436	197,027
Cash, end of the year	167,737	172,436
Supplemental Cash Flow Information:
Cash paid for interest	300,154	24,883
Non-Cash Investing and Financing Activities:
Deemed dividend on the redemption of preferred stock and accrued dividends for notes payable, common stock and exchange of warrants	6,484,236
Conversion of accounts payable and accrued liabilities to notes payable	2,555,189	100,000
Dividends on preferred stock and related interest	731,660	994,983
Issuance of common stock and common stock warrants for loan origination, amendment and extension fees	391,054	89,397
Assignment of related-party notes payable to an unrelated third party	263,082
Accrual of a liability to issue shares of common stock for loan origination fees	240,000
Issuance of common stock for consulting services	235,100	645,000
Cancellation and reissuance of shares of common stock	121,250
Conversion of related-party accounts payable and accrued liabilities to related-party notes payable	84,404	1,839,214
Issuance of common stock for related-party loan origination fees	70,000
Issuance of common stock for dividends	$ 18,617	$ 975,468

1. Organization and Nature of O

1. Organization and Nature of Operations	12 Months Ended
	Sep. 30, 2016
Notes
1. Organization and Nature of Operations	1. Organization and Nature of Operations ActiveCare, Inc. (“ActiveCare” or the “Company”) was formed March 5, 1998. In July 2009, ActiveCare was reincorporated in Delaware. The Company provides products and services to those diagnosed with chronic illnesses, provides real-time visibility to health conditions and risk, and has a unique active approach in caring for members. Going Concern The Company continues to incur negative cash flows from operating activities and net losses. The Company had minimal cash, negative working capital and negative total equity as of September 30, 2016 and 2015, and is in default with respect to certain debt. These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. In order for the Company to eliminate substantial doubt about its ability to continue as a going concern, it must achieve profitability, generate positive cash flows from operating activities and obtain the necessary debt or equity funding to meet its projected capital investment requirements. Management's plans with respect to this uncertainty consist of raising additional capital by issuing debt or equity securities and increasing the sales of the Company's services and products. There can be no assurance that the Company will be able to raise sufficient additional capital or that revenues will increase rapidly enough to achieve operating profits. If the Company is unable to increase revenues or obtain additional financing, it will be unable to continue the development of its products and services and may have to cease operations.

2. Summary of Significant Accou

2. Summary of Significant Accounting Policies	12 Months Ended
	Sep. 30, 2016
Notes
2. Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Principles of Accounting and Consolidation These consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“US GAAP”). The consolidated financial statements include the accounts of ActiveCare and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated. Use of Estimates in the Preparation of Financial Statements The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the balance sheet dates and the reported amounts of revenues and expenses for the reporting periods. Actual results could differ from these estimates. Discontinued Operations In December 2014, the Company sold substantially all of its customer contracts and equipment leased to customers associated with its CareServices segment to a third party. Additional equipment held in stock was sold to another third party pursuant to a written invoice. The purchase price included a cash payment of $412,280 for the customer contracts and $66,458 for the equipment held in stock. During fiscal years 2016 and 2015, the Company recognized a loss from discontinued operations related to CareServices of $0 and $186,232, respectively. Fair Value of Financial Instruments The Company measures the fair values of its assets and liabilities using the US GAAP hierarchy. The carrying amounts reported in the consolidated balance sheets for cash, accounts receivable, accounts payable, and accrued liabilities approximate fair values due to the short-term nature of these financial instruments. Derivative financial instruments are recorded at fair value based on current market pricing models. The carrying amounts reported for notes payable approximate fair values because the underlying instruments are at interest rates which approximate current market rates. Concentrations of Credit Risk The Company has cash in bank accounts that, at times, may exceed federally insured limits. The Company has not experienced any losses with respect to its deposited cash. In the normal course of business, the Company provides credit terms to its customers and requires no collateral. The Company performs ongoing credit evaluations of its customers’ financial condition. The Company maintains an allowance for doubtful accounts receivable based upon management’s specific review and assessment of each account at reporting period ends. For fiscal year 2016, the Company had revenues from two significant customers which represented 64% of total revenues. For fiscal year 2015, the Company had revenues from three significant customers which represented 69% of total revenues. As of September 30, 2016 and 2015, accounts receivable from significant customers represented 66% of total accounts receivable. For fiscal years 2016 and 2015, the Company purchased substantially all of its products and supplies from one vendor. Accounts Receivable Accounts receivable are carried at original invoice amount less an estimate made for doubtful accounts. Specific reserves are estimated by management based on certain assumptions and variables, including the customer’s financial condition, age of the customer’s receivables and changes in payment histories. Accounts receivable are written off when management determines the likelihood of collection is remote. A receivable is considered to be past due if any portion of the receivable balance has not been received by the contractual payment date. Interest is not charged on accounts receivable that are past due. The Company recorded an allowance for doubtful accounts of $75,161 and $30,495 as of September 30, 2016 and 2015, respectively. Inventory Inventory is recorded at the lower of cost or market value, cost being determined using the first-in, first-out ("FIFO") method. Inventory consists of diabetic supplies. Inventory held by distributors is reported as inventory until the supplies are shipped to the end user by the distributor. The Company estimates an inventory reserve for obsolescence and excessive quantities. Due to competitive pressures and technological innovation, it is possible that estimates of net realizable values could change in the near term. During the year ended September 30, 2016, the Company disposed of $563,128 of inventory for which a reserve for obsolescence had previously been recorded. Inventory consists of the following as of September 30: 2016 2015 Finished goods $ 206,444 $ 206,038 Finished goods held by distributors - 1,350,368 Total inventory 206,444 1,556,406 Inventory reserve (1,708 ) (813,935 ) Net inventory $ 204,736 $ 742,471 Property and Equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are determined using the straight-line method over the estimated useful lives of the assets, which range between 3 and 7 years. Leasehold improvements are amortized over the shorter of the estimated useful lives of the assets or the terms of the lease. Expenditures for maintenance and repairs are expensed as incurred. Upon the sale or disposal of property and equipment, any gains or losses are included in operations. Goodwill Goodwill is reviewed for impairment annually or more frequently when an event occurs or circumstances change that indicate that the carrying value may not be recoverable. The annual testing date is September 30. The identification and measurement of goodwill impairment involves the estimation of the fair value based on the best information available as of the date of the assessment, which primarily incorporates management assumptions about expected future cash flows and the Company’s overall market capitalization. Future cash flows can be affected by changes in industry or market conditions. Goodwill was impaired by $825,894 as of September 30, 2015 and no balance of goodwill remained. The impairment of goodwill was due to a potentially long-term reduction in the market capitalization of the Company subsequent to September 30, 2015. Impairment of Long-Lived Assets Purchased intangible assets with finite lives are amortized using the straight-line method over the estimated economic lives of the assets, which range from two to twenty years. Long-lived assets, including intangible assets with finite lives, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amounts of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. No long-lived assets with finite lives were considered to be impaired as of September 30, 2016 and 2015. Revenue Recognition For fiscal year 2015, revenues came from two sources: (1) sales of Chronic Illness Monitoring products and services; and (2) sales from CareServices. The CareServices segment was sold in December 2014 and, therefore, fiscal year 2016 only reflects revenues from Chronic Illness Monitoring. Information regarding revenue recognition policies relating to the Chronic Illness Monitoring and CareServices business segments is contained in the following paragraphs. Chronic Illness Monitoring Chronic Illness Monitoring revenues are recognized when persuasive evidence of an arrangement exists, delivery of the product or service to the end user has occurred, prices are fixed or determinable and collection is reasonably assured. The Company enters into agreements with insurance companies, disease management companies, third-party administrators, and self-insured companies (collectively, the customers) to lower medical expenses by distributing diabetic testing products and supplies to employees (end users) covered by their health plans or the health plans they manage. Cash is due from the customer or the end user’s health plan as the products and supplies are deployed to the end user. The Company also monitors the end user’s test results in real-time with its 24x7 CareCenter. Customers who are billed separately for monitoring are obligated to pay as the service is performed and revenue is recognized ratably over the period of the contract. The term of these contracts is generally one year and, unless terminated by either party, will automatically renew for another year. Collection terms are net 30 days after claims are submitted. There is no contingent revenue in these contracts. The Company also enters into agreements with distributors who take title to products and distribute those products to the end user. Delivery is considered to occur when the supplies are delivered by the distributor to the end user. Cash is due from the distributor, the customer or the end user’s health plan as initial products are deployed to the end user. Subsequent sales (resupplies) are shipped directly from the Company to the end user and cash is due from the customer or the end user’s health plan. Shipping and handling fees are typically not charged to end users. The related freight costs and supplies directly associated with shipping products to end users are included as a component of cost of revenues. Multiple-Element Arrangements Sales of Chronic Illness Monitoring products and services contain multiple elements. The Company evaluates each element in a multiple-element arrangement to determine whether it represents a separate unit of accounting. In order to account for elements in a multiple-element arrangement as separate units of accounting, the deliverables must have stand-alone value upon delivery. In determining whether monitoring services have stand-alone value, the nature of the Company’s monitoring services, whether the Company sells supplies to new customers without monitoring services, and availability of monitoring services from the other vendors are factors that are considered. When multiple elements included in an arrangement are separable into different units of accounting, the arrangement consideration is allocated to the identified separate units of accounting based on the relative selling prices. Multiple-element arrangements accounting guidance provides a hierarchy to use when determining the relative selling price for each unit of accounting. Vendor-specific objective evidence (VSOE) of selling price, based on the price at which the item is regularly sold by the vendor on a stand-alone basis, should be used if it exists. If VSOE of selling price is not available, third-party evidence (TPE) of selling price is used to establish the selling price if it exists. If VSOE of selling price and TPE of selling price are not available, then the best estimate of selling price is to be used. Total consideration under our multiple-element contracts is allocated to supplies and monitoring through application of the relative fair value method. CareServices CareServices included contracts in which the Company leased monitoring devices and provided monitoring services to end users as Personal Emergency Response System for the elderly (PERS; “I’ve fallen and can’t get up” service). The Company typically entered into contracts on a month-to-month basis with end users that used CareServices. These contracts could be cancelled by either party at any time with 30-days’ notice. Under a standard contract, the device and service became billable on the date the end user ordered the device, and remained billable until the device was returned to the Company. Revenues were recognized at the end of each month the service had been provided. In those circumstances in which payment was received in advance, the Company recorded deferred revenue. CareServices revenue was recognized when persuasive evidence of an arrangement existed, delivery of the device or service had occurred, prices were fixed or determinable, and collection was reasonably assured. Shipping and handling fees were included as part of net revenues. The related freight costs and supplies directly associated with shipping products to end users were included as a component of cost of revenues. All CareServices sales were made with net 30-day payment terms. The CareServices segment was sold in December 2014. Research and Development Costs All expenditures for research and development are charged to expense as incurred. Research and development expenses for fiscal years 2016 and 2015 were $248,441 and $106,526, respectively. The Company expects to continue investing in research and development as it develops new products and platforms for Chronic Illness Monitoring and as funds become available. Advertising Costs The Company expenses advertising costs as incurred. Advertising expenses for fiscal years 2016 and 2015 were $60,295 and $30,551, respectively. Advertising expenses primarily related to the Company’s Chronic Illness Monitoring segment for the fiscal years ended 2016 and 2015. Income Taxes The Company recognizes deferred income tax assets or liabilities for the expected future tax consequences of events that have been recognized in the financial statements or income tax returns. Deferred income tax assets or liabilities are determined based upon the difference between the financial reporting bases and tax reporting bases of assets and liabilities using enacted tax rates expected to apply when the differences are expected to be settled or realized. Deferred income tax assets are reviewed periodically for recoverability and valuation allowances are provided as necessary. As of September 30, 2016 and 2015, management has provided a 100% allowance against deferred income tax assets as it is more likely than not these assets will not be realized. Interest and penalties related to income tax liabilities, when incurred, are classified in interest expense and income tax provision, respectively. Warrant Exercises and Note Conversions The Company issues common shares in connection with warrant exercises when it has received verification that the proceeds have been deposited and when it has received an exercise letter from the warrant holder. The Company issues common shares in connection with note conversions after it verifies the outstanding note balance and the eligibility of conversion, and has received a conversion letter from the lender. Stock-Based Compensation The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized in the statements of operations over the period during which the employee is required to provide service in exchange for the award – the requisite service period. The grant-date fair values of the equity instruments are estimated using option-pricing models adjusted for the unique characteristics of those instruments. Net Loss Per Common Share Basic net loss per common share ("Basic EPS") is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the year. Diluted net loss per common share ("Diluted EPS") is computed by dividing net loss available to common stockholders by the sum of the weighted average number of common shares outstanding and the weighted-average dilutive common share equivalents outstanding. The computation of Diluted EPS does not assume exercise or conversion of securities that would have an anti-dilutive effect. Common share equivalents consist of shares issuable upon the exercise of common stock warrants and options, shares issuable from restricted stock grants, and shares issuable pursuant to convertible notes and convertible Series D, Series E and Series F preferred stock. The following table reflects the calculation of basic and diluted net loss per common share from continuing operations for the fiscal years ended September 30, 2016 and 2015: 2016 2015 Numerator: Net loss, excluding discontinued operations $ (16,338,456 ) $ (12,637,517 ) Effect of dilutive securities on net loss: Common stock options and warrants (1,857,070 ) - Total net loss for purpose of calculating diluted net loss per common share $ (18,195,526 ) $ (12,637,517 ) Number of shares used in per common share calculations: Total shares for purposes of calculating basic net loss per common share 96,669,000 51,444,000 Weighted-average effect of dilutive securities: Common stock options and warrants 1,378,503 - Total shares for purpose of calculating diluted net loss per common share 98,047,503 51,444,000 Net loss per common share: Basic $ (0.17 ) $ (0.25 ) Diluted $ (0.19 ) $ (0.25 ) The effect of dilutive securities on the numerator for purposes of calculating diluted loss per common share is related to the common stock options and warrants and convertible debt due to the reduction of the gain on derivatives liability. The following table reflects the calculation of basic and diluted net income per common share from discontinued operations for the years ended September 30, 2016 and 2015: 2016 2015 Numerator: Loss from discontinued operations $ - $ (186,232 ) Number of shares used in per common share calculations: Total shares for purposes of calculating basic net loss per common share 96,669,000 102,897 Weighted-average effect of dilutive securities: Common stock options and warrants 1,378,503 - Total shares for purpose of calculating diluted net loss per common share 98,047,503 102,897 Net loss per common share: Basic $ - $ - Diluted $ - $ - As of September 30, 2016 and 2015, there were certain outstanding common share equivalents that were not included in the computation of Diluted EPS as their effect would be anti-dilutive for the years then ended. The common stock equivalents outstanding consist of the following as of September 30, 2016 and 2015: 2016 2015 Common stock options and warrants 14,970,587 9,497,551 Series D convertible preferred stock 225,000 225,000 Series E convertible preferred stock 477,834 477,830 Series F convertible preferred stock - 16,065,328 Convertible debt 65,841,342 12,838,412 Restricted shares of common stock 7,500 7,500 Liability to issue common stock 3,692,308 - Total common stock equivalents 85,214,571 39,111,621 Reclassifications Certain prior year amounts have been reclassified to conform to the current year’s presentation. The reclassifications had no effect on the previously reported net loss. Recent Accounting Pronouncements In May 2014, August 2015 and May 2016, the Financial Accounting Standards Board (FASB) issued ASU 2014-09, Revenue from Contracts with Customers Revenue from Contracts with Customers, Deferral of the Effective Date Revenue from Contracts with Customers, Narrow-Scope Improvements and Practical Expedients In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern In November 2014, the FASB issued ASU 2014-16, Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity In April 2015 and August 2015, the FASB issued ASU 2015-03, Interest-Imputation of Interest: Simplifying the Presentation of Debt Issuance Costs Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements – Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting In June 2015, the FASB issued ASU 2015-10, Technical Corrections and Improvements In July 2015, the FASB issued ASU 2015-11, Inventory: Simplifying the Measurement of Inventory In February 2016, the FASB issued ASU 2016-02, Leases In March 2016, the FASB issued ASU 2016-09, Stock Compensation: Improvements to Employee Share-Based Payment Accounting In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments

3. Discontinued Operations

3. Discontinued Operations	12 Months Ended
	Sep. 30, 2016
Notes
3. Discontinued Operations	3. Discontinued Operations In December 2014, the Company sold substantially all of its customer contracts and equipment leased to customers associated with its CareServices segment. The sale included all segment assets that generated revenue related to the CareServices segment. The Company no longer holds any ownership interest in these assets and has ceased incurring costs related to the operations and development of the CareServices segment. This segment was engaged in the business of developing, distributing and marketing mobile health monitoring and concierge services to distributors and consumers. The debt secured by the CareServices customer contracts was amended in January 2015, December 2015, July 2016 and subsequent to September 30, 2016, and remains an obligation of the Company (see Notes 9 and 21). There were no material liabilities of discontinued operations as of September 30, 2016 and 2015. As a result of the sale of the CareServices assets, the Company has reflected this segment as discontinued operations in the consolidated financial statements for the fiscal year 2015. The following table summarizes certain operating data for discontinued operations for the fiscal years 2016 and 2015: 2016 2015 Revenues $ - $ 152,686 Cost of revenues - 127,709 Gross profit - 24,977 Selling, general and administrative expenses - (211,209 ) Loss from discontinued operations $ - (186,232 )

4. Prepaid Expenses and Other C

4. Prepaid Expenses and Other Current Assets	12 Months Ended
	Sep. 30, 2016
Notes
4. Prepaid Expenses and Other Current Assets	4. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following as of September 30: 2016 2015 Prepaid legal and professional fees $ 333,741 $ 2,500 Other 112,117 8,661 Research and development 96,346 - Prepaid information technology services 57,073 9,810 Line of credit acquisition fees 30,978 - Prepaid insurance 14,602 5,942 Prepaid consulting services - 291,648 Prepaid employee services - 205,000 Total prepaid expenses and other current assets $ 644,857 $ 523,561

5. Customer Contracts

5. Customer Contracts	12 Months Ended
	Sep. 30, 2016
Notes
5. Customer Contracts	5. Customer Contracts The Company sold substantially all of the CareServices customer contracts during December 2014. Amortization expense related to customer contracts in the CareServices segment for fiscal years 2016 and 2015 was $0 and $179,648, respectively.

6. Property, Plant and Equipmen

6. Property, Plant and Equipment Disclosure	12 Months Ended
	Sep. 30, 2016
Notes
6. Property, Plant and Equipment Disclosure	6. Property and Equipment Property and equipment consist of the following as of September 30: 2016 2015 Software $ 47,974 $ 100,574 Leasehold improvements 98,023 98,023 Furniture 68,758 68,758 Equipment 49,772 59,754 Total property and equipment 264,527 327,109 Accumulated depreciation and amortization (177,793 ) (191,339 ) Property and equipment, net $ 86,734 $ 135,770 Assets to be disposed of are reported at the lower of the carrying amounts or fair values, less the estimated costs to sell or dispose. During fiscal years 2016 and 2015, the Company recorded a loss on the disposal of assets of $2,780 and $42,336, respectively. During December 2014, the Company sold all of its equipment leased to customers (see Note 3). Depreciation expense for fiscal years 2016 and 2015 was $50,661 and $56,321, respectively.

7. Patents

7. Patents	12 Months Ended
	Sep. 30, 2016
Notes
7. Patents	7. Patents During fiscal year 2009, the Company licensed the use of certain patents from a third party. Under the license agreement, the Company was required to pay $300,000 plus a 5% royalty on the net sales of all licensed products. As of September 30, 2009, the Company capitalized the initial license fee as a long-term asset. During fiscal year 2012, the Company agreed to purchase the related patents and settle amounts owed under the license agreement by issuing 600,000 shares of common stock and 480,000 shares of Series C preferred stock. The patents were valued at $922,378 based on a valuation performed by an independent third party. The value of the common stock issued was $240,000, based on the market price of the common stock on the date of issuance. The implied value of the Series C was $682,378, which was based on the difference between the value of the patents and the common stock issued in settlement of the existing liability. Amortization expense for fiscal years 2016 and 2015 was $0 and $31,718, respectively. As of September 30, 2016 and 2015, patents totaling $514,046 have been fully amortized.

8. Accrued Expenses

8. Accrued Expenses	12 Months Ended
	Sep. 30, 2016
Notes
8. Accrued Expenses	8. Accrued Expenses Accrued expenses consisted of the following as of September 30: 2016 2015 Interest $ 1,206,387 $ 190,045 Liability to issue common stock 240,000 40,000 Payroll expense 207,052 270,974 Warranty liability 134,330 - Deferred revenue 111,803 147,344 Other 89,828 31,172 Severance 60,000 - Commissions and fees 52,311 64,432 Total accrued expenses $ 2,101,711 $ 743,967

9. Notes Payable

9. Notes Payable	12 Months Ended
	Sep. 30, 2016
Notes
9. Notes Payable	9. Notes Payable The Company had the following notes payable outstanding as of September 30: 2016 2015 Unsecured notes payable with interest at 10% per annum, due November 2018. The notes may go into default in the event other notes payable go into default subsequent to the effective date of the note. In February 2016, the Company redeemed all 5,361 shares of its Series F Convertible Preferred Stock ("Series F preferred") plus accrued dividends of $673,948 for 10,000,000 shares of common stock with a fair value of $1,600,000 containing certain temporary restrictions, and $5,900,000 of notes payable. Payments on the notes are partially or fully convertible at the Company's option at $0.30 per share to a maximum of 19,667,000 shares of common stock. The conversion rate is adjustable to any lower rates granted through equity sales or other conversion rates provided by issuances of other debt, warrants, options or other instruments, with the exception of certain other raises. A note may only be converted if the holder owns less than 4.99% of the Company’s common stock after conversion. The Company recorded a derivative liability of $2,461,899 related to the conversion feature of the notes. In connection with the redemption of the Series F preferred stock, the Company issued new warrants in exchange for warrants held by the Series F preferred stockholders for the purchase of 5,534,097 shares of common stock at an exercise price of $0.30 per common share, adjustable to any lower rates granted through equity sales or other conversion rates provided by issuances of other debt, warrants, options or other instruments, with the exception of certain other raises. The Company is also required to issue additional warrants for the purchase of up to 16,000 shares of common stock exercisable at $0.001 per share, also adjustable, that vest upon certain events of default. The fair value of $1,344,608 related to the new warrants was recorded as a derivative (see Notes 16 and 19). The fair value of the stock, conversion feature, warrants and $25,000 of fees, in excess of the carrying value of the Series F preferred stock were recorded as a deemed dividend of $6,484,236. Subsequent to September 30, 2016, the Company entered into letter agreements related to the note to convert the outstanding principal and interest into shares of common stock contingent upon a public offering proposed on Form S-1 originally filed with the SEC on July 19, 2016 (the “offering”) (see Note 21). $ 5,900,000 $ - Unsecured note payable with a vendor with interest at 0.65% per annum, due January 2018, issued in March 2016 upon the conversion of $2,523,937 in accounts payable to the vendor. $ 2,223,937 $ - Secured note payable to a third party with interest at 12.75% per annum, due February 2019. The note is secured by the assets of the Company and may go into default in the event other notes payable go into default subsequent to the effective date of the note. The Company entered into the note payable agreement in conjunction with a line of credit. The Company initially borrowed $1,500,000 and may borrow additional amounts under the note payable agreement up to a total balance of $3,000,000 as the Company meets certain milestones. The interest rate may also reduce to 11.25% per annum as the Company meets certain milestones. In conjunction with the note and related line of credit, the Company issued warrants to the lender to purchase 12,015,350 shares of common stock at $0.065 per share with a fair market value of $3,732,100 (see Notes 16 and 19), which resulted in a loss on derivative of $2,309,461. The Company has recorded discounts of $1,500,000, which are being amortized to interest expense over the term of the note. In April 2016, the Company borrowed an additional $500,000 on the note and incurred additional fees of $25,000, which are being amortized to interest expense over the remaining term of the note. Subsequent to September 30, 2016, the Company entered into forbearance agreements related to the note (see Note 21). 1,652,778 - Secured line of credit with a third party with interest at 12.25% per annum, due February 2018. The note is secured by the assets of the Company and may go into default in the event other notes payable go into default subsequent to the effective date of the note. The Company entered into the line of credit agreement in conjunction with a note payable. The Company may draw up to the lesser of 80% of certain accounts receivable or $1,500,000 and increase the maximum it may borrow under the agreement up to a total balance of $3,000,000 at $500,000 per increase as the Company meets certain milestones. The interest rate may also reduce to 10.75% per annum as the Company meets certain milestones. In conjunction with the line of credit and related note, the Company issued warrants to purchase 12,015,350 shares of common stock at $0.065 per share with a fair market value of $3,732,100 (see Notes 16 and 19), which resulted in a loss on derivative of $2,309,461. The Company has recorded prepaid expenses of $44,665, which are being amortized to interest expense over the term of the line of credit. 929,518 - Secured borrowings from a third party that purchased $1,658,000 of customer receivables for $1,230,000, with due dates ranging from September 2016 to April 2017, and payable in daily payments ranging from $2,454 to $3,996. The $269,000 difference between the customer receivables and cash received is being amortized to interest expense over the term of the respective notes. The secured borrowings are guaranteed by two officers of the Company and are subordinated to other notes payable. 689,318 - Unsecured note payable with a third party with no interest, due the earlier of November 2016 or the third business day after the closing of a proposed offering on Form S-1 filed on July 19, 2016. Pursuant to the note, the Company may borrow up to $1,500,000 upon meeting certain milestones. The note requires a payment of common stock on the 5th trading day after the pricing of the proposed offering, but no later than December 15, 2016. The number of common shares will equal $200,000 divided by the lowest of (i) the lowest daily closing price of the common stock during the ten days prior to delivery of the common shares or during the ten days prior to the date of the Purchase Agreement, (ii) 80% of the common stock offering price of the offering, (iii) 80% of the unit price offering price of the offering, or (iv) the exercise price of any warrants issued in the offering. The estimated fair value of $240,000 of the stock is included in accrued liabilities and is being amortized to interest expense over the life of the note. In connection with the issuance of the note, the Company also issued 10,000,000 warrants to purchase shares of common stock at an exercise price per share equal to the lesser of (i) 80% of the per share price of the common stock in the offering, (ii) $0.05 per share, (iii) 80% of the unit price in the offering, or (iv) the exercise price of any warrants issued in the offering and the number of shares will reset upon the closing of the offering. The warrants may only be exercised to the extent the holder would own a maximum of 9.99% of the Company’s common stock after exercise. The fair value of $493,590 related to the new warrants was recorded as a derivative (see Notes 16 and 19). Of this fair value amount, $220,000 was recorded as a debt discount and is being amortized over the life of the note and the remaining $273,590 was recorded as a loss on derivative liability. In the event of borrowing in excess of an initial $500,000, the Company will be required to issue additional warrants with an aggregate exercise amount equal to 100% of the additional amount borrowed with similar terms to the initial warrants issued. Subsequent to September 30, 2016, the Company borrowed the remaining $1,000,000 on the note and extended the maturity date (see Note 21). $ 500,000 $ - Note payable previously secured by CareServices customer contracts. In January 2015, the note was amended to reduce the outstanding principal to $375,000, interest at 9% per annum, and payable in 15 monthly installments beginning in February 2015. The amendment released the collateralized customer contracts and the note payable is guaranteed by both a former Executive Chairman of the Board of Directors and a member of the Board of Directors. A gain on the extinguishment of the old note of $769,449 was recorded in other income. In December 2015, the note was amended to extend maturity to January 2018 payable in monthly installments beginning in July 2016, convert $31,252 from accrued interest into principal, interest at 10% per annum, and provide that the note is convertible into common stock at its fair value per share. The Company recorded a derivative in connection with the convertible feature of the note (see Note 16) and is amortizing the initial $302,690 fair value of the derivative liability over the life of the note. In February 2016, the note was amended to subordinate to other notes payable also issued during February 2016. In July 2016, the note was amended to extend the maturity date to the earlier of an equity raise in excess of $10,000,000 or November 2016 and included additional default penalties and payment terms. In October 2016, the note was amended to extend the maturity date to the earlier of an equity raise in excess of $10,000,000 or February 15, 2017 and included additional default penalties and payment terms. 334,464 303,212 Unsecured note payable with interest at 12% per annum, due February 2016, convertible into common stock at $0.30 per share. In connection with the issuance of the note, the Company repriced previously issued warrants to purchase shares of common stock. The $22,397 increase in relative fair value of the warrants was included as a loss on the extinguishment of the old note in other expense in fiscal 2015. The note also required a payment of 3,000,000 shares of common stock. The fair value of $780,000 was included as a loss on the extinguishment of the old note in other expense in fiscal 2015. The maturity date was subsequently extended on two occasions for a total of 250,000 shares of common stock and the note was due May 2016. The $31,250 fair value of these shares was being amortized over the extension period. In February 2016, the note was amended to subordinate to other notes payable also issued during February 2016, and the conversion price was reduced to $0.06 per share, which was below the fair value of the Company’s common stock on the date of the amendment. The note may only be converted if the holder owns less than 9.99% of the Company’s common stock after conversion. The Company recorded the value of the beneficial conversion feature of $381,299 to loss on termination of debt as a result of the modification. In May 2016, the note was amended to extend the maturity date to the earlier of an equity raise of $10,000,000 or October 2016 which required a payment of 300,000 shares of common stock. The $28,500 fair value of these shares has been included in accrued liabilities and is being amortized over the extension period. Subsequent to September 30, 2016, the Company extended the maturity date of the note month-by-month through no later than April 30, 2017 for a fee of $5,000 per month extended (see Note 21). $ 300,000 $ 300,000 Unsecured note payable with interest at 12% per annum, due September 2016, subordinated to other notes payable. In connection with the issuance of the note, the Company issued 1,000,000 shares of common stock. The $100,000 fair value of the stock is being amortized to interest expense over the term of the note. Subsequent to September 30, 2016, the Company entered into a letter agreement related to the note to convert the outstanding principal and interest into shares of common stock contingent upon the completion of the offering (see Note 21). 250,000 - Secured note payable to a third party with interest at 18% per annum, due June 2017. The note is secured by shares of the Company's common stock held by, and other assets of an entity controlled by, a former Executive Chairman of the Board of Directors. The note is guaranteed by a former Executive Chairman of the Board of Directors and his related entity and may go into default in the event other notes payable go into default subsequent to the effective date of the note. Payments on the note are convertible at the holder's option into common stock at 75% of its fair value if not paid by its respective due date, which is subject to a 20 trading day true-up and is adjustable to any lower rates granted through equity sales or other conversion rates provided by issuances of other debt, warrants, options or other instruments, with the exception of other certain raises. The note may only be converted if the holder owns less than 4.99% of the Company’s common stock after conversion. The Company recognized a derivative liability related to the conversion feature with a fair value of $181,670, which was recognized as a loss on termination of debt. In June 2016, $13,713 of principal and $11,287 of accrued interest converted into 476,190 shares of common stock, pursuant to the terms of the note. In August 2016, $64,654 of principal and $10,346 of accrued interest converted into 4,601,226 shares of common stock, pursuant to the terms of the note. The note was terminated subsequent to September 30, 2016 (see Note 21). 162,539 - Unsecured notes with interest at 18% per annum, due April 2013, in default. The Company issued 20,000 shares of Series D preferred stock as loan origination fees. The $195,000 fair value of the preferred stock was amortized over the original term of the note. Principal of $50,000 and accrued interest of $13,333 were converted to common stock in December 2013. Subsequent to September 30, 2016, the Company entered into a letter agreement related to the remainder of the note to convert the outstanding principal and interest into shares of common stock contingent upon the completion of the offering (see Note 21). $ 64,261 $ 64,261 Secured borrowings from a third party that purchased $945,000 of customer receivables for $750,000, with due dates ranging from November 2015 to December 2016, payable in daily payments ranging from $955 to $1,909. The $195,000 difference between the customer receivables and cash received is being amortized to interest expense over the term of the respective notes. The secured borrowings are guaranteed by two officers of the Company. In November 2015, one of the notes was amended to subordinate to another note and to increase the principal by $28,385. The additional principal amount is being amortized to interest expense over the term of the note. In February 2016, the remaining principal balance on the borrowings of $417,160 was settled for a cash payment of $377,607, or 91% of the then outstanding balance, which resulted in a loss on termination of debt of $61,319. - 421,413 Secured borrowings from third parties that purchased a $337,600 customer receivable for $200,000. The Company repurchased the receivable for $233,333 less cash received by the third parties before June 2015. The $33,333 difference between the buyback and cash received, plus $20,000 of fees paid to a related party, was amortized to interest expense through June 2015. In February 2016, the notes were converted into 5,800,000 shares of common stock, at $0.04 per share, which was below the fair value of the Company’s stock on the date of conversion, which resulted in a loss on induced conversion of debt of $230,667. - 233,333 Unsecured notes payable with interest at 12% per annum, with due dates ranging from March 2016 to April 2016, convertible into common stock at a 15% discount from the 10-day volume adjusted weighted average closing price per share upon maturity. In connection with the issuance of the notes, the Company also issued 841,176 shares of common stock as an origination fee. The $119,205 fair value of the stock is being amortized to interest expense over the term of the notes. The notes included loan origination fees of $35,049, which are being amortized to interest expense over the term of the notes. The Company recorded a derivative liability in connection with the convertible feature of the notes (see Note 16) and is amortizing the initial $151,283 fair value of the derivatives liability over the life of the notes. In February 2016, the notes with outstanding principal balances totaling $350,490 plus accrued interest of $15,629 were converted into 9,287,985 shares of common stock at $0.04 per share, which was below the fair value of the Company’s stock on the date of conversion. The Company recognized a loss on induced conversion of debt of $148,465 and a gain on termination of debt of $64,099 in relation to the conversion. $ - $ 212,490 Total notes payable before discount 13,006,815 1,534,709 Less discount (1,930,060 ) (274,793 ) Total notes payable 11,076,755 1,259,916 Less current portion (3,722,899 ) (1,259,916 ) Notes payable, net of current portion $ 7,353,856 $ - As of September 30, 2016, scheduled principal payments on notes payable are as follows: Year Ending September 30, 2017 $ 4,946,767 2018 2,003,895 2019 6,056,153

10. Related-party Notes Payable

10. Related-party Notes Payable	12 Months Ended
	Sep. 30, 2016
Notes
10. Related-party Notes Payable	10. Related-Party Notes Payable 2016 2015 Secured borrowings from entities controlled by an officer who purchased a $2,813,175 customer receivable for $1,710,500. The Company repurchased the receivable for $1,950,000 less cash received by the entities through March 2015. The $239,500 difference between the buyback and cash received plus $253,500 of loan origination fees was amortized to interest expense through March 2015. In September 2015, the note was modified to extend the maturity date to January 2017, with interest at 18% per annum. The Company added $81,600 of extension fees and issued 3,000,000 shares of common stock to a lender as part of the modification. The note is convertible into common stock at $0.30 per share. The $540,000 fair value of the common stock was recognized as a loss on extinguishment of debt in fiscal 2015. In February 2016, the note was amended to subordinate to other notes payable also issued during February 2016, and the conversion price was reduced to $0.06 per share, which was below the fair value of the Company’s stock on the date of the amendment. The conversion of the note is now limited to a maximum of 20,000,000 common shares in combination with other convertible notes payable held by the lenders. The note has a default penalty of 4,203,389 shares of common stock, in combination with other convertible notes held by the lenders, if not paid by maturity. The Company recorded the value of the combined beneficial conversion features of $1,400,000 to loss on termination of debt as a result of the amendment. Subsequent to September 30, 2016, the Company entered into a letter agreement related to the secured borrowings to convert the outstanding principal and interest into shares of common stock contingent upon the completion of the offering (see Note 21). $ 1,721,100 $ 1,721,100 Unsecured note payable to an entity controlled by an officer with interest at 18% per annum, due January 2017, convertible into common stock at $0.30 per share. The Company issued 3,000,000 shares of common stock to a lender as loan origination fees. The $540,000 fair value of the common stock was recognized as a loss on extinguishment of debt in fiscal 2015. In February 2016, the note was amended to subordinate to other notes payable also issued during February 2016, and reduced the conversion price to $0.06 per share, which was below the fair value of the Company’s stock on the date of the amendment. The conversion of the note is now limited to a maximum of 20,000,000 common shares in combination with other convertible notes payable held by the lender. The note has a default penalty of 4,203,389 shares of common stock, in combination with other convertible notes held by the lender, if not paid by maturity. The Company recorded the value of the combined beneficial conversion features of $1,400,000 to loss on termination of debt as a result of the amendment. Subsequent to September 30, 2016, the Company entered into a letter agreement related to the note to convert the outstanding principal and interest into shares of common stock contingent upon the completion of the offering (see Note 21). 1,303,135 1,303,135 Unsecured note payable to an entity controlled by a former Executive Chairman of the Board of Directors with interest at 18% per annum, due January 2017. In February 2016, notes payable to the same entity, with outstanding balances of $511,005 plus accrued interest of $30,999 combined into this note. The note is subordinated to notes payable to unrelated parties and is convertible into shares of common stock at $0.06 per share, which was below the fair value of the Company’s stock on the date of the agreement. The conversion of the note is limited to a maximum of 9,250,000 common shares. The Company recorded the value of the beneficial conversion feature of $632,339 to loss on termination of debt. The note has a default penalty of 734,489 shares of common stock if not paid by maturity. The note may only be converted if the holder owns less than 4.99% of the Company’s common stock after conversion. Subsequent to September 30, 2016, the Company entered into a letter agreement related to the note to convert the outstanding principal and interest into shares of common stock contingent upon the completion of the offering (see Note 21). $ 542,004 $ - Unsecured note payable to an entity controlled by an officer with interest at 12% per annum, due September 2016, subordinated to other third party notes payable. In connection with the issuance of the note, the Company issued 1,000,000 shares of common stock. The $70,000 fair value of the stock is being amortized to interest expense over the term of the note. Subsequent to September 30, 2016, the Company entered into a letter agreement related to the note to convert the outstanding principal and interest into shares of common stock contingent upon the completion of the offering (see Note 21). 250,000 - Unsecured note payable to a former officer with interest at 12% per annum, due September 2013. This note is in default and is convertible into common stock at $0.75 per share. 26,721 26,721 Unsecured note payable to an entity controlled by an officer with interest at 18% per annum, due on demand. In February 2016, the note was amended to subordinate the note to other notes payable also issued during February 2016. The note is convertible into shares of common stock at $0.06 per share, which was below the fair value of the Company’s stock on the date of the amendment. The conversion of the note is now limited to a maximum of 20,000,000 common shares in combination with other convertible notes payable held by the entity. The note has a default penalty of 4,203,389 shares of common stock, in combination with other convertible notes held by the entity, if not paid by maturity. The Company recorded the value of the combined beneficial conversion features of $1,400,000 to loss on termination of debt as a result of the amendment. 25,463 25,463 Unsecured note payable to a former officer with interest at 15% per annum, due June 2012, in default. The note included a $3,000 loan origination fee added to the principal and is convertible into common stock at $0.50 per share. 17,227 30,000 Unsecured note payable to a former officer with interest at 12% per annum, due on demand. 12,474 13,644 Unsecured note payable to an entity controlled by a former Executive Chairman of the Board of Directors with no interest (18% per annum in the event of default), due on demand. The holder demanded payment by May 15, 2015. In February 2016, the note with an outstanding balance of $396,667 plus accrued interest of $53,403 was bifurcated into two notes payable of $243,082 and $206,988. The $243,082 bifurcated note plus $20,000 of the second bifurcated note was assigned to a third party and converted into a convertible note payable. The remaining $186,989 portion of the second bifurcated note, plus $3,521 of accrued interest, in combination with another note payable held by the entity in the amount of $324,016 plus $27,478 of related accrued interest, were converted into a convertible note payable of $542,004. $ - $ 396,667 Unsecured note payable to an entity controlled by a former Executive Chairman of the Board of Directors with interest at 18% per annum, due January 2017. In February 2016, the note with an outstanding balance of $324,016 plus accrued interest of $27,478, in combination with another note payable held by the entity of $186,989 plus $3,521 of accrued interest, were converted into a convertible note payable of $542,004. - 324,016 Total notes payable, related-party 3,898,124 3,840,746 Less current portion (3,898,124 ) (492,495 Notes payable, related-party, net of current portion $ - $ 3,348,251 As of September 30, 2016, scheduled principal payments on related-party notes payable are as follows: Year Ending September 30, 2017 $ 3,898,124

11. Loss On Induced Conversion

11. Loss On Induced Conversion of Debt and Sale of Common Stock	12 Months Ended
	Sep. 30, 2016
Notes
11. Loss On Induced Conversion of Debt and Sale of Common Stock	11. Loss on Induced Conversion of Debt and Sale of Common Stock During February 2016, the Company converted notes payable with outstanding principal balances totaling $233,333 into 5,800,000 shares of common stock, at $0.04 per common share, which was below the fair value of the Company’s stock on the date of conversion, which resulted in a loss on induced conversion of debt of $230,667. During February 2016, the Company converted notes payable with outstanding principal balances totaling $350,000 plus accrued interest of $16,000 into 9,287,985 shares of common stock, at $0.04 per common share, which was below the fair value of the stock on the date of conversion. The conversion resulted in a loss on induced conversion of debt of $148,465 and a gain on extinguishment of debt of $64,099.

12. Fair Value Measurements

12. Fair Value Measurements	12 Months Ended
	Sep. 30, 2016
Notes
12. Fair Value Measurements	12. Fair Value Measurements The Company measures the fair values of its assets and liabilities using the US GAAP hierarchy levels as follows: Level 1 The Company does not have any Level 1 inputs available to measure its assets. Level 2 Certain of the Company’s embedded derivative liabilities are measured on a recurring basis using Level 2 inputs. Level 3 Certain of the Company’s embedded derivative liabilities are measured on a recurring basis using Level 3 inputs. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Items measured at fair value on a recurring basis include embedded derivatives related to the Company’s warrants and notes payable. During fiscal 2016, the Company has not changed the manner in which it values liabilities that are measured at fair value using Level 3 inputs. The following fair value hierarchy table presents information about the Company's financial liabilities measured at fair value on a recurring basis: Quoted Prices in Active Markets for Identical Items (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total September 30, 2016 Derivatives liability $ - $ 281,613 $ 1,772,458 $ 2,054,071 September 30, 2015 Derivatives liability - 79,347 - 79,347 The following is a reconciliation of the opening and closing balances for the derivatives liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the fiscal year ended September 30, 2016: Derivatives Liability Balance, September 30, 2015 $ - Issuance of warrants recorded as derivatives 5,570,167 Issuance of embedded derivatives related to notes payable 2,643,569 Gain on derivatives liability resulting from changes in fair value (6,441,278 ) Balance, September 30, 2016 $ 1,772,458 The Company’s embedded derivatives liability is re-measured to fair value as of each reporting date. See Note 13 for more information about the valuation methods of derivatives and the inputs used for calculating fair value.

13. Derivatives Liability

13. Derivatives Liability	12 Months Ended
	Sep. 30, 2016
Notes
13. Derivatives Liability	13. Derivatives Liability The derivatives liability as of September 30, 2016 and 2015, was $2,054,071 and $79,347, respectively. The derivatives liability as of September 30, 2014, was related to a variable conversion price adjustment on the Series F preferred stock. The derivatives liability as of December 31, 2014, was eliminated due to the conversion price on Series F preferred stock being adjusted from $500.00 to $166.85 based on the number of subscribers as of December 31, 2014. The derivatives liability as of September 30, 2016 and 2015 is related to a variable conversion price adjustment on outstanding notes payable and warrants. A portion of derivatives liability as of December 31, 2015, and all of the derivatives outstanding as of September 30, 2015, were eliminated during February 2016, due to the conversion of notes payable into shares of common stock (see Note 9). During fiscal year 2016, the Company estimated the fair value of some of the embedded derivatives upon issuance, at the end of each reporting period and prior to their conversion and elimination using a binomial option-pricing model with the following assumptions, according to the instrument: exercise prices ranging from $0.03 to $0.09 per share; risk free interest rates ranging from 0.16% to 1.06%; expected lives ranging from 0.05 to 2.09 years; expected dividends of 0%; volatility factors ranging from 125.33% to 510.03%; and stock prices ranging from $0.03 to $0.14. During fiscal 2016, the Company estimated the fair value of the remaining embedded derivatives upon issuance and at the end of each reporting period using a Monte Carlo valuation model with the following assumptions: exercise prices ranging from $0.02 to $0.40 per share; risk free interest rates ranging from 0.18% to 1.44%; expected lives ranging from 0.04 to 6.40 years; expected dividends of 0%; volatility factors of 129% to 189%; and stock prices ranging from $0.02 to $0.40 per share. During the fiscal year ended September 30, 2015, the Company estimated the fair value of the embedded derivatives prior to their conversion and elimination using a binomial option-pricing model with the following assumptions, according to the instrument: exercise prices ranging from $0.12 to $0.33 per share; risk free interest rates ranging from 0.01% to 0.26%; expected lives ranging from 0.001 to 0.50 years; expected dividends of 0%; volatility factors ranging from 0.01% to 138.68%; and stock prices ranging from $0.12 to $0.33 per share. The expected lives of the instruments were equal to the average term of the conversion option or expected exercise period of the warrants. The expected volatility is based on the historical price volatility of the Company's common stock. The risk-free interest rate represents the US Treasury constant maturities rate for the expected life of the related conversion option. The dividend yield represents anticipated cash dividends to be paid over the expected life of the conversion option. The Company recognized a gain on derivatives liability for fiscal 2016 and 2015, of $3,405,035 and $128,942, respectively. Pursuant to agreements entered into subsequent to September 30, 2016, $1,772,458 of the derivatives liability will be eliminated upon the offering (see Note 21).

14. Preferred Stock

14. Preferred Stock	12 Months Ended
	Sep. 30, 2016
Notes
14. Preferred Stock	14. Preferred Stock The Company is authorized to issue 10,000,000 shares of preferred stock, with a par value of $0.00001 per share. Pursuant to the Company's Certificate of Incorporation, the Board of Directors has the authority to amend the Company's Certificate of Incorporation, without further stockholder approval, to designate and determine the preferences, limitations and relative rights of the preferred stock before any issuance of the preferred stock and to create one or more series of preferred stock, fix the number of shares of each such series, and determine the preferences, limitations and relative rights of each series of preferred stock, including dividend rights, dividend rates, conversion rights, voting rights, terms of redemption, redemption prices, and liquidation preferences. Series D Convertible Preferred Stock The Board of Directors has designated 1,000,000 shares of preferred stock as Series D Convertible Preferred Stock ("Series D preferred stock"). The Series D preferred stock votes on an as-converted basis. The Series D preferred stock has a dividend rate of 8%, payable quarterly. The Company may redeem the Series D preferred stock at a redemption price equal to 120% of the original purchase price with 15 days' notice. During the fiscal 2016 and 2015, the Company accrued $18,617 and $24,800 of dividends on Series D preferred stock, respectively, and settled $18,617 and $31,051 of accrued dividends, respectively, by issuing 302,517 and 118,068 shares of common stock, respectively. Subsequent to September 30, 2016, the Company entered into agreements with each of the Series D preferred stockholders to stop accruing dividends effective July 1, 2016. Subsequent to September 30, 2016, the Company entered into letter agreements with the holders of all Series D preferred shares to convert all outstanding shares of Series D preferred shares into shares of common stock contingent upon the completion of the offering (see Note 21). Series E Convertible Preferred Stock During fiscal 2013, the Board of Directors designated shares of preferred stock as Series E Convertible Preferred Stock ("Series E preferred stock"), convertible into common stock at $1.00 per share, adjustable if there are distributions of common stock or stock splits by the Company. The Series E preferred stock is non-voting and receives a monthly dividend of 3.322% for 25 to 32 months. In addition, the convertibility and the redemption price of the Series E preferred stock is gradually reduced by dividend payments over 25 to 32 months. After the dividend payment term, the redemption price of Series E preferred stock is $0, the Series E preferred stock has no convertibility to common stock and the holders are entitled to receive a pro-rata share of cumulative royalties totaling 4% of the Company's gross profits payable quarterly for a two-year period. During fiscal 2014, $83,473 of debenture loans and accrued interest converted into 8,347 shares of Series E preferred stock. During fiscal 2016 and 2015, the Company accrued dividends of $217,895 and $326,863, respectively, payable to Series E preferred stockholders. As of September 30, 2016 and 2015, the aggregate redemption price for the Series E preferred stock was $477,829. Subsequent to September 30, 2016, the Company entered into a letter agreement with a director, who owns 13,843 of Series E preferred shares, who agreed to convert these Series E preferred shares into shares of common stock, contingent upon the completion of the offering (see Note 21). Series F Convertible Preferred Stock During fiscal 2014, the Board of Directors designated 7,803 shares of preferred stock as Series F Convertible Preferred Stock ("Series F preferred stock"). In April 2014, the Company increased the authorized shares of Series F preferred stock to 10,000. Series F preferred stock is non-voting, has a stated value of $1,000 per share and is convertible into common stock at $0.3337 per share (see Note 13). The Series F preferred stock has a dividend rate, payable quarterly, of 8% until April 30, 2015, 16% from May 1, 2015 to July 31, 2015, 20% from August 1, 2015 to October 31, 2015, and 25% thereafter. In February 2016, the Company redeemed all 5,361 outstanding shares and $673,848 of accrued dividends for 10,000,00 shares of common stock, $5,900,000 of notes payable and exchanged warrants for the purchase of 5,534,097 shares of common stock held by Series F preferred stockholders for new warrants with new terms for the purchase of the same number of shares (see Note 16). The Company recorded a deemed dividend of $6,484,236 as a result of the transactions. During fiscal 2014, the Company issued 5,361 858 4,503 Liquidation Preference Upon any liquidation, dissolution or winding up of the Company, before any distribution or payment may be made to the holders of the common stock, the holders of the Series D preferred stock, Series E preferred stock, and Series F preferred stock are entitled to be paid out of the assets an amount equal to $1.00 per share plus all accrued but unpaid dividends. If the assets of the Company are insufficient to make payment in full to all holders of preferred stock, then the assets shall be distributed among the holders of preferred stock ratably in proportion to the full amounts to which they would otherwise be entitled.

15. Common Stock

15. Common Stock	12 Months Ended
	Sep. 30, 2016
Notes
15. Common Stock	15. Common Stock In April 2014, the Company amended its Certificate of Incorporation increasing the total number of authorized shares of common stock from 50,000,000 shares to 200,000,000 shares. During fiscal 2016, the Company issued the following shares of common stock: · · · · · · · · · The fair value of unvested common stock as of September 30, 2016 was $405,000.

16. Common Stock Options and Wa

16. Common Stock Options and Warrants	12 Months Ended
	Sep. 30, 2016
Notes
16. Common Stock Options and Warrants	16. Common Stock Options and Warrants The fair value of each stock option or warrant is estimated on the date of grant using a binomial option-pricing model or the Monte Carlo valuation model. The expected life of stock options or warrants represents the period of time that the stock options or warrants are expected to be outstanding, based on the simplified method. Expected volatilities are based on historical volatility of the Company's common stock, among other factors. The Company uses the simplified method within the binomial option-pricing valuation model due to the Company's short trading history. The risk-free rate related to the expected term of the stock options or warrants is based on the US Treasury yield curve in effect at the time of grant. The dividend yield is zero. During fiscal 2016, the Company granted warrants to purchase 12,015,350 common shares with an exercise price of $0.065 per share in connection with the acquisition of a note payable and line of credit; warrants for the purchase of 7,392,800 shares vested immediately, 1,847,550 vested upon the disbursement of the second tranche of the related note payable, and 2,775,000 vest evenly in the event of three available increases on the related line of credit (see Note 9). The warrants expire in February 2023, may be settled in a cashless exercise, and are puttable upon expiration or liquidation for the greater of $500,000 or up to 6.5% of the equity value of the Company, depending on the number of warrants vested. The fair value of the warrants upon grant of $3,731,969 was recorded as a derivative and the Company received cash of $2,967 upon issuance of the warrants. The Company recognized $1,419,541 as debt discount for the portion allocated to the note payable and the debt discount is being amortized over the life of the note payable to interest expense. During September 2016, the Company entered into a conditionally effective warrant cancellation agreement with the warrant holders (see Note 19). During February 2016, the Company exchanged warrants held by the holders of its Series F preferred stock for the purchase of 5,534,097 shares of common stock in connection with the redemption of Series F preferred stock for new warrants for the purchase of the same number of shares on different terms. The new warrants were initially exercisable for $0.30 per share, adjustable to any lower rates granted through equity sales or other conversion rates provided by issuances of other debt, warrants, options or other instruments, with the exception of certain other raises. During September 2016, the Company issued warrants for the purchase of common stock that adjusted the warrants to have an exercise price per share equal to the lesser of (i) 80% of the per share price of the common stock of the offering, (ii) $0.05 per share, (iii) 80% of the unit price in the offering (if applicable), or (iv) the exercise price of any warrants issued in the offering. The new warrants expire in February 2021, and may be settled in a cashless exercise. Additional warrants for the purchase of 8,000,000 shares of common stock may be issued in the event of default on the related notes payable, exercisable at $0.001 per share, with 25% issuable upon the first event of default, 37.5% upon the second event, and 37.5% upon the third event. The warrants issuable upon default expire in February 2026 (if issued), may be settled in a cashless exercise, and are puttable upon expiration or liquidation with the primary warrants. The new warrants may only be exercised to the extent the respective holder would own a maximum of 4.99% of the Company’s common stock after exercise, but the holders may elect to increase the maximum to 9.99%. The Company recognized a deemed dividend of $6,484,236 as a result of the exchange and related redemption of Series F preferred stock. During September 2016, the Company granted warrants to purchase 10,000,000 shares in connection with the acquisition of a note payable at an exercise price per share equal to the lesser of (i) 80% of the per share price of the common stock of the offering, (ii) $0.05 per share, (iii) 80% of the unit price in the offering (if applicable), or (iv) the exercise price of any warrants issued in the offering. Upon the closing of the offering, the number of shares issuable under the warrant will reset to an amount of shares equal to the aggregate exercise amount of the warrants (as defined therein) divided by the exercise price then in effect. The warrants expire in September 2021, and may be settled in a cashless exercise. The warrants may only be exercised to the extent the holder would own a maximum of 9.99% of the Company’s common stock after exercise. The Company recognized $220,000 of the $493,590 fair value of the warrants as a debt discount, which is being amortized over the life of the borrowing, and recognized the remaining $273,590 as a loss on derivatives liability. In the event the Company borrows additional amounts above the initial $500,000 under the note payable, the Company will be required to issue additional warrants with an aggregate exercise amount equal to 100% of the additional amount borrowed with similar terms to warrants issued as part of the initial borrowing. Subsequent to September 30, 2016, the Company borrowed an additional $700,000 on the note and issued warrants for the purchase of 14,000,000 shares of common stock with the same terms as the initial warrants. During fiscal 2016, the Company granted warrants to purchase 1,333,333 shares with an exercise price of $0.30 per share in connection with the acquisition of a note payable (see Note 9). The warrants expire in November 2020. The fair value of the warrants upon grant of $130,254 was recorded as a debt discount and was amortized over the life of the note payable to interest expense. During fiscal 2016 and 2015, the Company measured the fair value of warrants classified as equity instruments using a binomial valuation model with the following assumptions: 2016 2015 Exercise price $0.30 $0.30 - $1.00 Expected term (years) 5 1 - 2 Volatility 219% 228% - 302% Risk-free rate 1.57% 0.22%- 0.63% Dividend rate 0% 0% During fiscal 2016, the Company measured the fair value of warrants classified as liabilities on the date of issuance and on each re-measurement date using the Monte Carlo valuation model. For this liability, the Company and specialist developed their own assumptions that do not have observable inputs or available market data to support the fair value. This method of valuation involves using inputs such as the fair value of the Company’s common stock, stock price volatility, the contractual term of the warrants, risk–free interest rates and dividend yields. Due to the nature of these inputs, the valuation of the warrants uses Level 3 measurements. The following assumptions were used: Exercise price $0.02 - $[A1] 0.30[A2] Expected term (years) 4.09 – [A3] 6.40 Volatility 134% - 189% Risk-free rate 0.91% - 1.44% Dividend rate 0% Common stock price $0.02 - $0.40 The following table summarizes information about stock options and warrants outstanding as of September 30, 2016: Options and Warrants Number of Options and Warrants Weighted- Average Exercise Price Outstanding as of October 1, 2015 9,497,551 $ 0.91 Granted 28,882,780 0.07 Cancelled (326,200 ) 0.81 Forfeited (5,534,097 ) 1.10 Outstanding as of September 30, 2016 32,520,037 0.13 Exercisable as of September 30, 2016 28,015,034 0.11 During fiscal 2015, the Company did not grant any common stock options or warrants, and 1,494,025 options and warrants were forfeited. During February 2015, the Company modified the exercise price of options and warrants previously issued to a former Executive Chairman of the Board of Directors from $1.00 to $0.30 per share, according to an agreement entered into prior to appointment as the Executive Chairman, and recognized additional expense of $20,472. During April 2015, the Company modified the exercise price of options and warrants previously issued to a note holder from $1.00 to $0.40 per share as part of a settlement agreement and conversion of an existing note payable and other payables into a new note payable. The additional expense of $22,397 was recorded as a loss on extinguishment of debt. As of September 30, 2016, the outstanding warrants had an aggregate intrinsic value of $0 and the weighted average remaining term of the warrants was 5 years. The total compensation cost related to unvested awards not yet recognized (options, warrants, and shares) was $69,728.

17. Segment Information

17. Segment Information	12 Months Ended
	Sep. 30, 2016
Notes
17. Segment Information	17. Segment Information The Company operated one business segment during fiscal 2016. The Company operated two business segments during fiscal 2015, based primarily on the nature of the Company's products. The Chronic Illness Monitoring segment is engaged in the business of developing, distributing and marketing mobile monitoring of patient vital signs and physical activity to insurance companies, disease management companies, third-party administrators, and self-insured companies. The customer contracts and equipment leased to customers of the Company’s CareServices segment were sold in December 2014, and that segment was discontinued. The CareServices segment was engaged in the business of developing, distributing and marketing mobile health monitoring and concierge services to distributors and consumers. At the corporate level, the Company raises capital and provides for the administrative operations of the Company as a whole. The following table reflects certain financial information relating to each reportable segment as of September 30, 2016 and 2015, and for the fiscal years then ended: Corporate Chronic Illness Monitoring CareServices (Discontinued Operations) Total As of September 30, 2016 and for the Fiscal Year Then Ended: Sales to external customers $ - $ 7,464,146 $ - $ 7,464,146 Segment income (loss) (10,151,704 ) 1,029,144 - (9,122,560 ) Interest expense, net 2,963,747 - - 2,963,747 Segment assets 926,469 691,737 - 1,618,206 Property and equipment purchases 5,004 - - 5,004 Depreciation and amortization 51,376 - - 51,376 As of September 30, 2015 and for the Fiscal Year Then Ended: Sales to external customers $ - $ 6,597,981 $ 152,686 $ 6,750,667 Segment loss (10,757,547 ) (583,890 ) (186,232 ) (11,527,669 ) Interest expense, net 977,234 - - 977,234 Segment assets 767,302 1,771,658 - 2,538,960 Property and equipment purchases 15,289 - - 15,289 Depreciation and amortization 57,036 - 233,664 290,700

18. Income Taxes

18. Income Taxes	12 Months Ended
	Sep. 30, 2016
Notes
18. Income Taxes	18. Income Taxes As of September 30, 2016, the Company had net operating loss carryforwards available to offset future taxable income, if any, of approximately $89,295,000, which will begin to expire in 2027. The utilization of the net operating loss carryforwards is dependent upon the tax laws in effect at the time the net operating loss carryforwards can be utilized. The Internal Revenue Code contains provisions that likely could reduce or limit the availability and utilization of these net operating loss carryforwards. For example, limitations are imposed on the utilization of net operating loss carryforwards if certain ownership changes have taken place or will take place. The Company will perform an analysis to determine whether any such limitations have occurred as the net operating losses are utilized. The amount and ultimate realization of the benefits from the net operating loss carryforwards are dependent, in part, upon the tax laws in effect, the Company’s future earnings, and other future events, the effects of which cannot be determined. The Company has established a valuation allowance against all deferred income tax assets not offset by deferred income tax liabilities due to the uncertainty of their realization. Accordingly, there is no benefit for income taxes in the accompanying statements of operations. Deferred income taxes are determined based on the estimated future effects of differences between the consolidated financial reporting and income tax reporting bases of assets and liabilities given the provisions of currently enacted tax laws and the tax rates expected to be in place. The deferred income tax assets (liabilities) were comprised of the following as of September 30: 2016 2015 Net operating loss carryforwards $ 33,307,000 $ 29,000,000 Depreciation, amortization and reserves 442,000 721,000 Stock-based compensation 1,619,000 1,728,000 Accrued vacation 23,000 28,000 Valuation allowance (35,391,000 ) (31,477,000 ) Total $ - $ - Reconciliations between the benefit for income taxes at the federal statutory income tax rate and the Company’s benefit for income taxes for fiscal 2016 and 2015 were as follows: 2016 2015 Federal income tax benefit at statutory rate $ 3,102,000 $ 3,919,000 State income tax benefit, net of federal income tax effect 300,000 380,000 Permanent differences 498,000 (367,000 ) Other 14,000 112,000 Change in valuation allowance (3,914,000 ) (4,044,000 ) Benefit for income taxes $ - $ - During fiscal 2016 and 2015, the Company recognized no interest or penalties, and there were no changes in unrecognized tax benefits from tax positions taken or from lapsed statutes of limitations. There were no settlements with taxing authorities. As of September 30, 2016, the Company had no unrecognized tax benefits that, if recognized, would affect the effective tax rate, and there are no positions that are anticipated to significantly increase or decrease. The Company had no tax examinations beginning, ending, or remaining in process as of and for the years ended September 30, 2016 and 2015. Tax returns for fiscal years subsequent to 2012 remain subject to examination.

19. Commitments and Contingenci

19. Commitments and Contingencies	12 Months Ended
	Sep. 30, 2016
Notes
19. Commitments and Contingencies	19. Commitments and Contingencies During fiscal 2015, the Company leased office space under a non-cancelable operating lease. In February 2015, the Company entered into a sublease agreement for part of the office space under the non-cancelable operating lease through the end of the original lease period. Payments under the sublease were made by the sublessee directly to the Company's landlord. The non-cancelable operating lease was terminated during June 2015. The Company's rent expense for facilities under the terminated operating lease for the nine months ended June 30, 2015, was approximately $226,000. During June 2015, the Company entered into a new non-cancelable operating lease for its existing office space, excluding the previously subleased space, with payments beginning in July 2015. Future minimum rental payments under the non-cancelable operating lease as of September 30, 2016, were as follows: Years Ending September 30, 2017 $ 130,036 2018 111,340 $ 241,376 The Company's rent expense under the new non-cancelable operating lease for fiscal 2016 and 2015, was approximately $126,000 and $31,000, respectively. During February 2016, the Company entered into an agreement with one if its vendors to purchase a minimum of $200,000 of inventory per quarter through January 2018. During February 2016, the Company redeemed all of its Series F preferred stock in exchange for 10,000,000 shares of common stock and $5,900,000 of notes payable (see Note 9). As part of the redemption, the Company exchanged warrants held by the Series F Preferred stockholders for the purchase of 5,534,097 shares of common stock for new warrants to purchase the same number of shares with different terms. As part of the redemption, the Company may be required to issue additional warrants for the purchase of up to 8,000,000 shares of common stock upon three events of default on the notes payable (see Note 16). During February 2016, the Company converted notes payable and accrued interest payable to an entity controlled by a former Executive Chairman of the Board of Directors into a convertible note payable (see Note 10). The Company may be required to issue 734,489 shares of common stock if the note is not paid by maturity. During February 2016, the Company amended notes payable to an entity controlled by an officer of the Company to subordinate to notes payable also issued during February 2016, reduced the conversion price per share to $0.06 per share and limited the shares into which it is convertible (see Note 10). The Company may be required to issue 4,203,389 shares of common stock if the note is not paid by maturity. During September 2016, the Company issued a note payable to a third party for up to $1,500,000. The Company initially borrowed $500,000 under the note and may borrow up to $1,500,000 upon meeting certain milestones. In the event the Company borrows additional amounts above initial $500,000, the Company will be required to issue additional warrants with an aggregate exercise amount equal to 100% of the additional amount borrowed with similar terms to warrants issued as part of the initial borrowing. Subsequent to September 30, 2016, the Company borrowed the remaining $1,000,000 on the note (see Note 21). During September 2016, the Company entered into a conditionally effective warrant cancellation agreement (the “Warrant Cancellation Agreement”) with certain warrant holders who were issued the warrants in connection with a secured note payable and line of credit. Pursuant to the terms of the Warrant Cancellation Agreement, upon the Company’s consummation of an equity financing of at least $15,000,000, the warrant holders agree to terminate and cancel the warrants they currently hold. As an inducement to enter into the Warrant Cancellation Agreement, the warrant holders will receive upon termination and cancelation of the warrants an aggregate of 5,400,000 shares of the Company’s common stock, which will be subject to a 6-month lock-up agreement. Additionally, if the warrant holders terminate and cancel the warrants, the Company will issue the related note holder a new unsecured promissory note with an initial principal amount of $180,000, no cash interest, and a three-year term. In lieu of cash interest, the principal of the note will increase in the amount $3,333 each month not to exceed a maximum of $300,000. On May 28, 2015, an investor of the Company filed a lawsuit claiming damages of $1,000,000 exclusive of interest and costs against the Company, a former Executive Chairman, an entity controlled by another former Executive Chairman, and 4G Biometrics, a wholly owned subsidiary of the Company, for breach of contract. The Company has engaged legal counsel regarding the matter. It is not possible to predict the outcome of the matter at this time. The Company intends to vigorously dispute the claims and believes it has meritorious defenses. On November 4, 2015, the Company received a demand for payment of $275,000 from a former employee of the Company and former principal of 4G Biometrics whose employment was terminated for cause. On December 4, 2015, the Company filed a complaint against the former owners of 4G Biometrics, including this former employee, seeking damages in excess of $300,000 related to alleged misrepresentations made to induce the Company to acquire 4G Biometrics. Between February 4, 2016 and February 8, 2016, the Company settled the complaint with each of the former owners of 4G Biometrics and all parties released each other from all outstanding claims, including any current monetary obligations to each party, excluding one former owner of 4G Biometrics who continues to be employed by the Company. A Stipulation for Order of Dismissal with Prejudice of all Claims and Counterclaims has been filed and is in the process of being approved. The settlement resulted in the termination of $39,863 of related-party accounts payable. Subsequent to September 30, 2016, the Company entered into additional contingent arrangements (see Note 21).

20. Related Party Transactions

20. Related Party Transactions Not Otherwise Disclosed	12 Months Ended
	Sep. 30, 2016
Notes
20. Related Party Transactions Not Otherwise Disclosed	20. Related Party Transactions Not Otherwise Disclosed During fiscal 2015, an entity controlled by the Company’s former Executive Chairman of the Board of Directors consulted with the Company to enter into an agreement with a customer. The Company granted the entity 250,000 shares of common stock with a fair value of $53,500. The Company also agreed to pay the entity 8.5% of revenue from this customer as long as the sales contract remains in full force. During September 2015, the Company entered into consulting agreements with an entity controlled by the former Executive Chairman of the Board of Directors. The Company agreed to pay for the former Executive Chairman’s healthcare insurance cost plus $6,000 per month for consulting services. The Company also agreed to pay as a bonus to the entity a fee equal to 15% of the funds raised less payments to third parties owed in regards to the funds raised. The Company paid $180,000 in bonuses and fees related to this agreement to the entity during fiscal 2016. In February 2016, the Company amended the consulting agreement, effective January 2016. The amendment extended the agreement through December 2016, with monthly automatic renewals, adjusted the monthly compensation of $6,000 to an hourly rate of $250 per hour, and eliminated the previously included bonus structure. During September 2015, the Company entered into a one-year consulting agreement with an entity controlled by the Chief Executive Officer, who had previously assumed a new role as Chief Financial Officer of the Company. The Company agreed to pay the entity $20,000 per month and 2,000,000 shares of common stock with a fair value of $360,000. In July 2016, the Company entered into a consulting agreement with a former Executive Chairman and Chief Executive Officer of the Company. This consulting agreement is for an initial period of one year, and shall automatically renew for consecutive one month periods unless terminated by the Company or the former Executive Chairman and Chief Executive Officer. As consideration for the services previously described, the Company shall pay the former Executive Chairman and Chief Executive Officer at the rate of $250 per hour, but such compensation may not exceed $20,000 during any calendar month.

21. Subsequent Events

21. Subsequent Events	12 Months Ended
	Sep. 30, 2016
Notes
21. Subsequent Events	21. Subsequent Events Subsequent to September 30, 2016, the Company entered into the following agreements and transactions: (1) On November 1, 2016, the Company filed a Certificate of Amendment (the “Amendment”) to its Certificate of Incorporation to effectuate a 1-for-500 reverse stock split (the "Reverse Split"). On January 12, 2017, the Company filed a Certificate of Correction to the Amendment in order to clarify that such Reverse Split will not become effected until such time as it is processed and announced by the Financial Industry Regulatory Authority (“FINRA”). As of January 13, 2017, the Reverse Split has not yet been processed and announced by FINRA. No warrant, option, share and per share information in this report gives effect to this Reverse Split. (2) Effective November 1, 2016, the Board approved the 2016 Incentive Stock Option plan providing for the issuance of options to purchase up to 188,625,000 shares. (3) On September 9, 2016, the Company and a senior secured lender entered into a Forbearance Loan and Security Agreement (the “September Forbearance Agreement”). Pursuant to the terms of the September Forbearance Agreement, the lender will forbear from exercising remedies (the “Forbearance”) with regard to certain breaches of agreements between the Company through October 31, 2016 and consented to the Company entering into a purchase agreement with another party and issue the note and the warrant thereunder. Effective November 1, 2016, the Company and the lender entered into a forbearance and consent under loan and security agreement (the “November Forbearance Agreement”). Pursuant to the terms of the November Forbearance Agreement, the lender will forbear from exercising remedies (the “November Forbearance”) with regard to certain breaches of agreements between the Company and the lender, including the existing agreements as well as the September Forbearance Agreement. Additionally, pursuant to the November Forbearance Agreement, the lender has provided the Company with the consent required under the Existing Agreements and September Forbearance Agreement to make certain payments from the proceeds of the offering. These payments include, but are not limited to (i) payments to holders of the Company’s Series E Preferred Stock, (ii) third party note and receivable payments and (iii) repayment of an unsecured note payable issued in September 2016. The lender also consented to the issuance of the Company’s Series G Preferred Stock to certain affiliates of the Company. In consideration for the November Forbearance, the Company has agreed to issue the lender warrants to purchase 65,000,000 shares of common stock at an exercise price equal to the per share price of the common stock in the offering, which shall be subject to a 12-month lock-up agreement. The Forbearance set forth in the November Forbearance Agreement will be in effect through December 31, 2016. Effective December 31, 2016, the Company and the lender entered into a forbearance and consent under loan and security agreement (the “December Forbearance”). Pursuant to the terms of the December Forbearance, the lender will forbear from exercising remedies with regard to certain breaches of agreements between the Company and the lender, including the existing agreements as well as the September Forbearance and November Forbearance. Additionally, pursuant to the December Forbearance, the lender has provided the Company with the consent required under the Existing Agreements, September Forbearance and November Forbearance to make certain payments from the proceeds of the offering. In consideration for the December Forbearance, the Company has agreed to issue the lender warrants to purchase 5,000,000 shares of common stock at an exercise price equal to the per share price of the common stock in the offering and $50,000 of common stock at 80% of the at the same issue price in of the offering, which shall be subject to a lock-up agreement. The forbearance set forth in the December Forbearance will be in effect through February 15, 2017. (4) On January 12, 2017, the Company entered into letter agreements (together the “Note Holder Letter Agreements”) with eight (8) investors (each a “Note Holder” and together the “Note Holders”) holding convertible notes payable whereby the Note Holders agreed to convert all monies due them under the Notes into restricted shares of common stock (the “Note Conversion Shares”) and warrants to purchase common stock (the “Note Conversion Warrants” and together with the Note Conversion Shares, the “Note Conversion Securities”), all contingent upon the completion of the offering. As incentive to enter into the Note Holder Letter Agreements, the Company agreed to add approximately $1,687,811 to the outstanding principal and interest as of October 31, 2016, effectively making the total obligation due to Note Holders an aggregate of $8,000,000 (the “Total Note Obligation”). Pursuant to the Note Holder Letter Agreements, the Total Note Obligation will automatically convert upon consummation of the offering into the Note Conversion Securities at the combined price per share and warrant paid by investors in the offering (the “Conversion Price”). The terms of the Note Conversion Warrants will be substantially similar to the Warrants being included in the offering, except such Note Conversion Warrants will be a restricted security and will not publicly trade on NASDAQ. In addition, the Note Holders currently hold warrants to purchase an aggregate of 5,534,097 shares that will be terminated upon the consummation of the offering. In consideration of such termination, the Note Holders will be issued new warrants to purchase an identical number of shares of Common Stock at an exercise price equal to the Conversion Price, as defined in the agreements. Each person entering into the Note Holder Letter Agreements have entered into lock-up agreements prohibiting the sale or other transfer of any securities of the Company owned by such persons for a period of 6 months. If the offering is not completed by February 15, 2017, the Note Holder Letter Agreements and lock-up agreements will terminate. (5) On January 12, 2017, the Company entered into a letter agreement with a third-party lender, whereby the lender agreed to convert all monies due under that certain subordinated promissory note into common stock of the Company, contingent upon the completion of the offering. As of September 30, 2016, the aggregate amount of $101,814 was owed pursuant to the note. Pursuant to the letter agreement, the aggregate amount owed, together with interest accruing subsequent to September 30, 2016, will automatically convert upon consummation of the offering into such number of restricted shares of the Company’s common stock calculated by dividing the aggregate amount owed by 80% of the per share price of the common stock in the offering. The lender has entered into a lock-up agreement prohibiting the sale or other transfer of all securities of the Company owned for a period of 6 months. If the offering is not completed by February 15, 2017, the letter agreement and lock-up agreement will terminate. (6) On January 12, 2017, the Company entered into a letter agreement with a third-party lender, whereby the lender agreed to convert all monies due him under that certain subordinated promissory note into common stock of the Company, contingent upon the completion of the offering. As of September 30, 2016 the aggregate amount of $265,616 was owed pursuant to the note. Pursuant to the letter agreement, the aggregate amount owed, together with interest accruing subsequent to September 30, 2016, will automatically convert upon consummation of the offering into such number of restricted shares of the Company’s common stock calculated by dividing the aggregate amount owed by 80% of the per share price of the common stock in the offering. The lender has entered into a lock-up agreement prohibiting the sale or other transfer of all securities of the Company owned by him for a period of 6 months. The letter agreement extends the due date of the note to the earlier of the offering or February 15, 2017. (7) On January 12, 2017, the Company entered into a letter agreement with a third-party vendor, whereby such vendor agreed to convert all monies due from the Company pursuant to certain accounts payable into common stock of the Company, contingent upon the completion of the offering. As of September 30, 2016, the aggregate amount of $73,667 was owed to the vendor. Pursuant to the letter agreement, the aggregate amount owed will automatically convert upon consummation of the offering into such number of restricted shares of the Company’s common stock calculated by dividing the aggregate amount owed by the per share price of the common stock in the offering. The vendor has entered into a lock-up agreement prohibiting the sale or other transfer of all securities of the Company owned by it for a period of 6 months. If the offering is not completed by February 15, 2017, the letter agreement and lock-up agreement will terminate. (8) On January 12, 2017, the Company entered into a letter agreement with a director of the Company whereby the director agreed to convert all monies due him from the Company from unpaid board service fees into common stock of the Company, contingent upon the completion of the offering. As of October 31, 2016, the aggregate amount of $42,500 was owed to the director. Pursuant to the letter agreement, the unpaid fees will automatically convert upon consummation of the offering into such number of restricted shares of the Company’s common stock calculated by dividing the unpaid fees by $0.035 or 1,214,286 shares. The director has entered into a lock-up agreement prohibiting the sale or other transfer of all securities of the Company owned by him for a period of 12 months. If the offering is not completed by February 15, 2017, the letter agreement and lock-up agreement will terminate. (9) On January 12, 2017, the Company entered into a second letter agreement with the director, whereby the director agreed to convert 13,843 shares of Series E Preferred Stock of the Company owned into common stock of the Company, contingent upon the completion of the offering. As of September 30, 2016, the aggregate amount of $181,297 consisting of accrued dividends, royalty and interest was owed to the director with respect to his Series E Preferred Stock. Pursuant to the second letter agreement, the aggregate amount will automatically convert upon consummation of the offering into such number of restricted shares of the Company’s common stock calculated by dividing the aggregate amount by $0.035 or 5,116,421 shares. The director has entered into a lock-up agreement prohibiting the sale or other transfer of all securities of the Company owned for a period of 12 months. If the offering is not completed by February 15, 2017, the letter agreement and lock-up agreement will terminate. (10) On January 12, 2017, the Company entered into a letter agreement with entities controlled by the Chief Executive Officer, whereby each of such parties agreed to convert all monies due pursuant to three separate promissory notes into common stock of the Company, contingent upon the completion of the offering. As of September 30, 2016, the aggregate amount of $3,876,737 was owed to the holders pursuant to the notes payable. Pursuant to the letter agreement, the aggregate amount owed, together with interest accruing subsequent to September 30, 2016, will automatically convert upon consummation of the offering into such number of restricted shares of the Company’s common stock calculated by dividing the aggregate amount owed by $0.045, or 86,149,712 shares, exclusive of interest accruing subsequent to September 30, 2016. Each of the parties subject to the letter agreement have entered into a lock-up agreement prohibiting the sale or other transfer of all securities of the Company owned by such parties for a period of 12 months. The letter agreement extends the due date of the notes to the earlier of the offering or February 15, 2017. (11) On January 12, 2017, the Company entered into a letter agreement with an entity controlled by a former Executive Chairman and a current consultant to the Company, whereby the entity agreed to convert all monies due it under a promissory note into common stock of the Company, contingent upon the completion of the offering. As of September 30, 2016, the aggregate amount of $602,145 was owed to the entity pursuant to the promissory note. Pursuant to the letter agreement, the aggregate amount owed, together with interest accruing subsequent to September 30, 2016, will automatically convert upon consummation of the offering into such number of restricted shares of the Company’s common stock calculated by dividing the aggregate amount owed by $0.045 or 13,381,004 shares, exclusive of interest accruing subsequent to September 30, 2016. The entity has entered into a lock-up agreement prohibiting the sale or other transfer of all securities of the Company owned by it for a period of 12 months. If the offering is not completed by February 15, 2017, the letter agreement and lock-up agreement will terminate. (12) On January 12, 2017, the Company entered into a letter agreement with a third-party investor, whereby the investor agreed to convert 20,000 shares of Series D Preferred Stock of the Company owned into common stock of the Company based on current redemption value contingent upon the completion of the offering. As of the date hereof, the current redemption value of such Series D Preferred Stock was $72,000. Pursuant to the letter agreement, the redemption value will automatically convert upon consummation of the offering into such number of restricted shares of the Company’s common stock calculated by dividing the redemption value by 80% of the per share price of the common stock in the offering and all dividends cease accruing beginning July 1, 2016. The investor has entered into a lock-up agreement prohibiting the sale or other transfer of all securities of the Company owned by him for a period of 12 months. If the offering is not completed by February 15, 2017, the letter agreement and lock-up agreement will terminate. (13) On January 12, 2017, the Company entered into a letter agreement with an entity affiliated with the Chief Executive Officer, whereby the entity agreed to convert 25,000 shares of Series D Preferred Stock of the Company owned into common stock of the Company based on current redemption value, contingent upon the completion of the offering. As of the date hereof, the current redemption value of such Series D Preferred Stock was $300,000. Pursuant to the letter agreement, the redemption value will automatically convert upon consummation of the offering into such number of restricted shares of the Company’s common stock calculated by dividing the redemption value by $0.045 or 6,666,666 shares and all dividends cease accruing beginning July 1, 2016. The entity has entered into a lock-up agreement prohibiting the sale or other transfer of all securities of the Company owned by it for a period of 12 months. If the offering is not completed by February 15, 2017, the letter agreement and lock-up agreement will terminate. (14) On November 3, 2016, the Company drew an additional $250,000 on a note payable where it may borrow up to $1,500,000. The Company issued warrants to purchase 5,000,000 shares of common stock at an exercise price per share equal to the lesser of (i) 80% of the per share price of the common stock of the offering, (ii) $0.05 per share, (iii) 80% of the unit price in the offering (if applicable), or (iv) the exercise price of any warrants issued in the offering. In connection with the draw of additional funds, the lender provided new conditions on October 31, 2016 for the Company to be able to draw funds. (15) On November 17, 2016, the Company amended a note payable where it may borrow up to $1,500,000 to extend the maturity date to the earlier of January 31, 2017 or the third business day after the closing of the offering. In addition, the amendment adjusted the origination shares to equal 20% of the note divided by the lowest of (i) the lowest daily closing price of the common stock during the ten days prior to delivery of the shares or during the ten days prior to the date of the agreement, (ii) 80% of the common stock offering price of the offering, (iii) 80% of the unit price offering price (if applicable), or (iv) 80% of the exercise price of any warrants issued in the offering. (16) On December 28, 2016, the Company drew an additional $250,000 on a note payable where it may borrow up to $1,500,000. The Company issued warrants to purchase 5,000,000 shares of common stock at an exercise price per share equal to the lesser of (i) 80% of the per share price of the common stock of the offering, (ii) $0.05 per share, (iii) 80% of the unit price in the offering (if applicable), or (iv) the exercise price of any warrants issued in the offering. (17) On January 3, 2017, the Company drew an additional $200,000 on a note payable where it may borrow up to $1,500,000. The Company issued warrants to purchase 4,000,000 shares of common stock at an exercise price per share equal to the lesser of (i) 80% of the per share price of the common stock of the offering, (ii) $0.05 per share, (iii) 80% of the unit price in the offering (if applicable), or (iv) the exercise price of any warrants issued in the offering. (18) On August 19, 2016, the Company received a cash advance from an entity controlled by a former Executive Chairman and consultant in the amount of $135,000 and $100,000 of this amount was repaid subsequent to year end. (19) On October 3, 2016, the Company sold $210,000 of future customer receipts to a third party for $150,000 in cash. The $60,000 difference between the future customer receipts and cash received by the Company is being amortized to interest expense over the term of the note. The note is subordinated to another note. (20) On December 6, 2016, the Company sold $560,000 of future customer receipts to a third party for $400,000 in cash. The $160,000 difference between the future customer receipts and cash received by the Company is being amortized to interest expense over the term of the note. The note is subordinated to another note. (21) From October through December 2016, the Company received cash advances from third parties in the amount of $717,500 and repaid $124,000, inclusive of fees. (22) On October 31, 2016, the Company amended a convertible note payable to a third party to extend the maturity date month-by-month through no later than April 30, 2017 for a fee of $5,000 per month. (23) On October 31, 2016, the Company amended a note payable with principal balance of $334,464 to extend the maturity date to the earlier of the offering or December 31, 2016. On December 8, 2016, the Company further amended the note to extend the maturity date to the earlier of the offering or February 15, 2017. (24) On December 16, 2016, the Company sold $225,750 of future customer receipts to a third party for $175,000 in cash. The $50,750 difference between the future customer receipts and cash received by the Company is being amortized to interest expense over the term of the note. The note is subordinated to another note. (25) On January 3, 2017, the Company terminated a secured note payable with a principal balance of $162,539 as of September 30, 2016. No additional consideration was given as part of the termination.

1. Organization and Nature of29

1. Organization and Nature of Operations: Going Concern (Policies)	12 Months Ended
	Sep. 30, 2016
Policies
Going Concern	Going Concern The Company continues to incur negative cash flows from operating activities and net losses. The Company had minimal cash, negative working capital and negative total equity as of September 30, 2016 and 2015, and is in default with respect to certain debt. These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. In order for the Company to eliminate substantial doubt about its ability to continue as a going concern, it must achieve profitability, generate positive cash flows from operating activities and obtain the necessary debt or equity funding to meet its projected capital investment requirements. Management's plans with respect to this uncertainty consist of raising additional capital by issuing debt or equity securities and increasing the sales of the Company's services and products. There can be no assurance that the Company will be able to raise sufficient additional capital or that revenues will increase rapidly enough to achieve operating profits. If the Company is unable to increase revenues or obtain additional financing, it will be unable to continue the development of its products and services and may have to cease operations.

2. Summary of Significant Acc30

2. Summary of Significant Accounting Policies: Use of Estimates in The Preparation of Financial Statements (Policies)	12 Months Ended
	Sep. 30, 2016
Policies
Use of Estimates in The Preparation of Financial Statements	Use of Estimates in the Preparation of Financial Statements The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the balance sheet dates and the reported amounts of revenues and expenses for the reporting periods. Actual results could differ from these estimates.

2. Summary of Significant Acc31

2. Summary of Significant Accounting Policies: Discontinued Operations, Policy (Policies)	12 Months Ended
	Sep. 30, 2016
Policies
Discontinued Operations, Policy	Discontinued Operations In December 2014, the Company sold substantially all of its customer contracts and equipment leased to customers associated with its CareServices segment to a third party. Additional equipment held in stock was sold to another third party pursuant to a written invoice. The purchase price included a cash payment of $412,280 for the customer contracts and $66,458 for the equipment held in stock. During fiscal years 2016 and 2015, the Company recognized a loss from discontinued operations related to CareServices of $0 and $186,232, respectively.

2. Summary of Significant Acc32

2. Summary of Significant Accounting Policies: Fair Value of Financial Instruments (Policies)	12 Months Ended
	Sep. 30, 2016
Policies
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company measures the fair values of its assets and liabilities using the US GAAP hierarchy. The carrying amounts reported in the consolidated balance sheets for cash, accounts receivable, accounts payable, and accrued liabilities approximate fair values due to the short-term nature of these financial instruments. Derivative financial instruments are recorded at fair value based on current market pricing models. The carrying amounts reported for notes payable approximate fair values because the underlying instruments are at interest rates which approximate current market rates.

2. Summary of Significant Acc33

2. Summary of Significant Accounting Policies: Concentrations of Credit Risk (Policies)	12 Months Ended
	Sep. 30, 2016
Policies
Concentrations of Credit Risk	Concentrations of Credit Risk The Company has cash in bank accounts that, at times, may exceed federally insured limits. The Company has not experienced any losses with respect to its deposited cash. In the normal course of business, the Company provides credit terms to its customers and requires no collateral. The Company performs ongoing credit evaluations of its customers’ financial condition. The Company maintains an allowance for doubtful accounts receivable based upon management’s specific review and assessment of each account at reporting period ends. For fiscal year 2016, the Company had revenues from two significant customers which represented 64% of total revenues. For fiscal year 2015, the Company had revenues from three significant customers which represented 69% of total revenues. As of September 30, 2016 and 2015, accounts receivable from significant customers represented 66% of total accounts receivable. For fiscal years 2016 and 2015, the Company purchased substantially all of its products and supplies from one vendor.

2. Summary of Significant Acc34

2. Summary of Significant Accounting Policies: Accounts Receivable (Policies)	12 Months Ended
	Sep. 30, 2016
Policies
Accounts Receivable	Accounts Receivable Accounts receivable are carried at original invoice amount less an estimate made for doubtful accounts. Specific reserves are estimated by management based on certain assumptions and variables, including the customer’s financial condition, age of the customer’s receivables and changes in payment histories. Accounts receivable are written off when management determines the likelihood of collection is remote. A receivable is considered to be past due if any portion of the receivable balance has not been received by the contractual payment date. Interest is not charged on accounts receivable that are past due. The Company recorded an allowance for doubtful accounts of $75,161 and $30,495 as of September 30, 2016 and 2015, respectively.

2. Summary of Significant Acc35

2. Summary of Significant Accounting Policies: Inventory (Policies)	12 Months Ended
	Sep. 30, 2016
Policies
Inventory	Inventory Inventory is recorded at the lower of cost or market value, cost being determined using the first-in, first-out ("FIFO") method. Inventory consists of diabetic supplies. Inventory held by distributors is reported as inventory until the supplies are shipped to the end user by the distributor. The Company estimates an inventory reserve for obsolescence and excessive quantities. Due to competitive pressures and technological innovation, it is possible that estimates of net realizable values could change in the near term. During the year ended September 30, 2016, the Company disposed of $563,128 of inventory for which a reserve for obsolescence had previously been recorded. Inventory consists of the following as of September 30: 2016 2015 Finished goods $ 206,444 $ 206,038 Finished goods held by distributors - 1,350,368 Total inventory 206,444 1,556,406 Inventory reserve (1,708 ) (813,935 ) Net inventory $ 204,736 $ 742,471

2. Summary of Significant Acc36

2. Summary of Significant Accounting Policies: Property, Plant and Equipment, Policy (Policies)	12 Months Ended
	Sep. 30, 2016
Policies
Property, Plant and Equipment, Policy	Property and Equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are determined using the straight-line method over the estimated useful lives of the assets, which range between 3 and 7 years. Leasehold improvements are amortized over the shorter of the estimated useful lives of the assets or the terms of the lease. Expenditures for maintenance and repairs are expensed as incurred. Upon the sale or disposal of property and equipment, any gains or losses are included in operations.

2. Summary of Significant Acc37

2. Summary of Significant Accounting Policies: Goodwill (Policies)	12 Months Ended
	Sep. 30, 2016
Policies
Goodwill	Goodwill Goodwill is reviewed for impairment annually or more frequently when an event occurs or circumstances change that indicate that the carrying value may not be recoverable. The annual testing date is September 30. The identification and measurement of goodwill impairment involves the estimation of the fair value based on the best information available as of the date of the assessment, which primarily incorporates management assumptions about expected future cash flows and the Company’s overall market capitalization. Future cash flows can be affected by changes in industry or market conditions. Goodwill was impaired by $825,894 as of September 30, 2015 and no balance of goodwill remained. The impairment of goodwill was due to a potentially long-term reduction in the market capitalization of the Company subsequent to September 30, 2015.

2. Summary of Significant Acc38

2. Summary of Significant Accounting Policies: Impairment of Long-lived Assets (Policies)	12 Months Ended
	Sep. 30, 2016
Policies
Impairment of Long-lived Assets	Impairment of Long-Lived Assets Purchased intangible assets with finite lives are amortized using the straight-line method over the estimated economic lives of the assets, which range from two to twenty years. Long-lived assets, including intangible assets with finite lives, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amounts of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. No long-lived assets with finite lives were considered to be impaired as of September 30, 2016 and 2015.

2. Summary of Significant Acc39

2. Summary of Significant Accounting Policies: Revenue Recognition (Policies)	12 Months Ended
	Sep. 30, 2016
Policies
Revenue Recognition	Revenue Recognition For fiscal year 2015, revenues came from two sources: (1) sales of Chronic Illness Monitoring products and services; and (2) sales from CareServices. The CareServices segment was sold in December 2014 and, therefore, fiscal year 2016 only reflects revenues from Chronic Illness Monitoring. Information regarding revenue recognition policies relating to the Chronic Illness Monitoring and CareServices business segments is contained in the following paragraphs. Chronic Illness Monitoring Chronic Illness Monitoring revenues are recognized when persuasive evidence of an arrangement exists, delivery of the product or service to the end user has occurred, prices are fixed or determinable and collection is reasonably assured. The Company enters into agreements with insurance companies, disease management companies, third-party administrators, and self-insured companies (collectively, the customers) to lower medical expenses by distributing diabetic testing products and supplies to employees (end users) covered by their health plans or the health plans they manage. Cash is due from the customer or the end user’s health plan as the products and supplies are deployed to the end user. The Company also monitors the end user’s test results in real-time with its 24x7 CareCenter. Customers who are billed separately for monitoring are obligated to pay as the service is performed and revenue is recognized ratably over the period of the contract. The term of these contracts is generally one year and, unless terminated by either party, will automatically renew for another year. Collection terms are net 30 days after claims are submitted. There is no contingent revenue in these contracts. The Company also enters into agreements with distributors who take title to products and distribute those products to the end user. Delivery is considered to occur when the supplies are delivered by the distributor to the end user. Cash is due from the distributor, the customer or the end user’s health plan as initial products are deployed to the end user. Subsequent sales (resupplies) are shipped directly from the Company to the end user and cash is due from the customer or the end user’s health plan. Shipping and handling fees are typically not charged to end users. The related freight costs and supplies directly associated with shipping products to end users are included as a component of cost of revenues. Multiple-Element Arrangements Sales of Chronic Illness Monitoring products and services contain multiple elements. The Company evaluates each element in a multiple-element arrangement to determine whether it represents a separate unit of accounting. In order to account for elements in a multiple-element arrangement as separate units of accounting, the deliverables must have stand-alone value upon delivery. In determining whether monitoring services have stand-alone value, the nature of the Company’s monitoring services, whether the Company sells supplies to new customers without monitoring services, and availability of monitoring services from the other vendors are factors that are considered. When multiple elements included in an arrangement are separable into different units of accounting, the arrangement consideration is allocated to the identified separate units of accounting based on the relative selling prices. Multiple-element arrangements accounting guidance provides a hierarchy to use when determining the relative selling price for each unit of accounting. Vendor-specific objective evidence (VSOE) of selling price, based on the price at which the item is regularly sold by the vendor on a stand-alone basis, should be used if it exists. If VSOE of selling price is not available, third-party evidence (TPE) of selling price is used to establish the selling price if it exists. If VSOE of selling price and TPE of selling price are not available, then the best estimate of selling price is to be used. Total consideration under our multiple-element contracts is allocated to supplies and monitoring through application of the relative fair value method. CareServices CareServices included contracts in which the Company leased monitoring devices and provided monitoring services to end users as Personal Emergency Response System for the elderly (PERS; “I’ve fallen and can’t get up” service). The Company typically entered into contracts on a month-to-month basis with end users that used CareServices. These contracts could be cancelled by either party at any time with 30-days’ notice. Under a standard contract, the device and service became billable on the date the end user ordered the device, and remained billable until the device was returned to the Company. Revenues were recognized at the end of each month the service had been provided. In those circumstances in which payment was received in advance, the Company recorded deferred revenue. CareServices revenue was recognized when persuasive evidence of an arrangement existed, delivery of the device or service had occurred, prices were fixed or determinable, and collection was reasonably assured. Shipping and handling fees were included as part of net revenues. The related freight costs and supplies directly associated with shipping products to end users were included as a component of cost of revenues. All CareServices sales were made with net 30-day payment terms. The CareServices segment was sold in December 2014.

2. Summary of Significant Acc40

2. Summary of Significant Accounting Policies: Research and Development Costs (Policies)	12 Months Ended
	Sep. 30, 2016
Policies
Research and Development Costs	Research and Development Costs All expenditures for research and development are charged to expense as incurred. Research and development expenses for fiscal years 2016 and 2015 were $248,441 and $106,526, respectively. The Company expects to continue investing in research and development as it develops new products and platforms for Chronic Illness Monitoring and as funds become available.

2. Summary of Significant Acc41

2. Summary of Significant Accounting Policies: Advertising Costs (Policies)	12 Months Ended
	Sep. 30, 2016
Policies
Advertising Costs	Advertising Costs The Company expenses advertising costs as incurred. Advertising expenses for fiscal years 2016 and 2015 were $60,295 and $30,551, respectively. Advertising expenses primarily related to the Company’s Chronic Illness Monitoring segment for the fiscal years ended 2016 and 2015.

2. Summary of Significant Acc42

2. Summary of Significant Accounting Policies: Income Taxes (Policies)	12 Months Ended
	Sep. 30, 2016
Policies
Income Taxes	Income Taxes The Company recognizes deferred income tax assets or liabilities for the expected future tax consequences of events that have been recognized in the financial statements or income tax returns. Deferred income tax assets or liabilities are determined based upon the difference between the financial reporting bases and tax reporting bases of assets and liabilities using enacted tax rates expected to apply when the differences are expected to be settled or realized. Deferred income tax assets are reviewed periodically for recoverability and valuation allowances are provided as necessary. As of September 30, 2016 and 2015, management has provided a 100% allowance against deferred income tax assets as it is more likely than not these assets will not be realized. Interest and penalties related to income tax liabilities, when incurred, are classified in interest expense and income tax provision, respectively.

2. Summary of Significant Acc43

2. Summary of Significant Accounting Policies: Stock-based Compensation (Policies)	12 Months Ended
	Sep. 30, 2016
Policies
Stock-based Compensation	Stock-Based Compensation The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized in the statements of operations over the period during which the employee is required to provide service in exchange for the award – the requisite service period. The grant-date fair values of the equity instruments are estimated using option-pricing models adjusted for the unique characteristics of those instruments.

2. Summary of Significant Acc44

2. Summary of Significant Accounting Policies: Net Loss Per Common Share (Policies)	12 Months Ended
	Sep. 30, 2016
Policies
Net Loss Per Common Share	Net Loss Per Common Share Basic net loss per common share ("Basic EPS") is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the year. Diluted net loss per common share ("Diluted EPS") is computed by dividing net loss available to common stockholders by the sum of the weighted average number of common shares outstanding and the weighted-average dilutive common share equivalents outstanding. The computation of Diluted EPS does not assume exercise or conversion of securities that would have an anti-dilutive effect. Common share equivalents consist of shares issuable upon the exercise of common stock warrants and options, shares issuable from restricted stock grants, and shares issuable pursuant to convertible notes and convertible Series D, Series E and Series F preferred stock. The following table reflects the calculation of basic and diluted net loss per common share from continuing operations for the fiscal years ended September 30, 2016 and 2015: 2016 2015 Numerator: Net loss, excluding discontinued operations $ (16,338,456 ) $ (12,637,517 ) Effect of dilutive securities on net loss: Common stock options and warrants (1,857,070 ) - Total net loss for purpose of calculating diluted net loss per common share $ (18,195,526 ) $ (12,637,517 ) Number of shares used in per common share calculations: Total shares for purposes of calculating basic net loss per common share 96,669,000 51,444,000 Weighted-average effect of dilutive securities: Common stock options and warrants 1,378,503 - Total shares for purpose of calculating diluted net loss per common share 98,047,503 51,444,000 Net loss per common share: Basic $ (0.17 ) $ (0.25 ) Diluted $ (0.19 ) $ (0.25 ) The effect of dilutive securities on the numerator for purposes of calculating diluted loss per common share is related to the common stock options and warrants and convertible debt due to the reduction of the gain on derivatives liability. The following table reflects the calculation of basic and diluted net income per common share from discontinued operations for the years ended September 30, 2016 and 2015: 2016 2015 Numerator: Loss from discontinued operations $ - $ (186,232 ) Number of shares used in per common share calculations: Total shares for purposes of calculating basic net loss per common share 96,669,000 102,897 Weighted-average effect of dilutive securities: Common stock options and warrants 1,378,503 - Total shares for purpose of calculating diluted net loss per common share 98,047,503 102,897 Net loss per common share: Basic $ - $ - Diluted $ - $ - As of September 30, 2016 and 2015, there were certain outstanding common share equivalents that were not included in the computation of Diluted EPS as their effect would be anti-dilutive for the years then ended. The common stock equivalents outstanding consist of the following as of September 30, 2016 and 2015: 2016 2015 Common stock options and warrants 14,970,587 9,497,551 Series D convertible preferred stock 225,000 225,000 Series E convertible preferred stock 477,834 477,830 Series F convertible preferred stock - 16,065,328 Convertible debt 65,841,342 12,838,412 Restricted shares of common stock 7,500 7,500 Liability to issue common stock 3,692,308 - Total common stock equivalents 85,214,571 39,111,621

2. Summary of Significant Acc45

2. Summary of Significant Accounting Policies: Reclassifications (Policies)	12 Months Ended
	Sep. 30, 2016
Policies
Reclassifications	Reclassifications Certain prior year amounts have been reclassified to conform to the current year’s presentation. The reclassifications had no effect on the previously reported net loss.

2. Summary of Significant Acc46

2. Summary of Significant Accounting Policies: Recent Accounting Pronouncements (Policies)	12 Months Ended
	Sep. 30, 2016
Policies
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, August 2015 and May 2016, the Financial Accounting Standards Board (FASB) issued ASU 2014-09, Revenue from Contracts with Customers Revenue from Contracts with Customers, Deferral of the Effective Date Revenue from Contracts with Customers, Narrow-Scope Improvements and Practical Expedients In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern In November 2014, the FASB issued ASU 2014-16, Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity In April 2015 and August 2015, the FASB issued ASU 2015-03, Interest-Imputation of Interest: Simplifying the Presentation of Debt Issuance Costs Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements – Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting In June 2015, the FASB issued ASU 2015-10, Technical Corrections and Improvements In July 2015, the FASB issued ASU 2015-11, Inventory: Simplifying the Measurement of Inventory In February 2016, the FASB issued ASU 2016-02, Leases In March 2016, the FASB issued ASU 2016-09, Stock Compensation: Improvements to Employee Share-Based Payment Accounting In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments

2. Summary of Significant Acc47

2. Summary of Significant Accounting Policies: Inventory: Schedule of Utility Inventory (Tables)	12 Months Ended
	Sep. 30, 2016
Tables/Schedules
Schedule of Utility Inventory	2016 2015 Finished goods $ 206,444 $ 206,038 Finished goods held by distributors - 1,350,368 Total inventory 206,444 1,556,406 Inventory reserve (1,708 ) (813,935 ) Net inventory $ 204,736 $ 742,471

2. Summary of Significant Acc48

2. Summary of Significant Accounting Policies: Net Loss Per Common Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)	12 Months Ended
	Sep. 30, 2016
Tables/Schedules
Schedule of Earnings Per Share, Basic and Diluted	2016 2015 Numerator: Net loss, excluding discontinued operations $ (16,338,456 ) $ (12,637,517 ) Effect of dilutive securities on net loss: Common stock options and warrants (1,857,070 ) - Total net loss for purpose of calculating diluted net loss per common share $ (18,195,526 ) $ (12,637,517 ) Number of shares used in per common share calculations: Total shares for purposes of calculating basic net loss per common share 96,669,000 51,444,000 Weighted-average effect of dilutive securities: Common stock options and warrants 1,378,503 - Total shares for purpose of calculating diluted net loss per common share 98,047,503 51,444,000 Net loss per common share: Basic $ (0.17 ) $ (0.25 ) Diluted $ (0.19 ) $ (0.25 ) The effect of dilutive securities on the numerator for purposes of calculating diluted loss per common share is related to the common stock options and warrants and convertible debt due to the reduction of the gain on derivatives liability. The following table reflects the calculation of basic and diluted net income per common share from discontinued operations for the years ended September 30, 2016 and 2015: 2016 2015 Numerator: Loss from discontinued operations $ - $ (186,232 ) Number of shares used in per common share calculations: Total shares for purposes of calculating basic net loss per common share 96,669,000 102,897 Weighted-average effect of dilutive securities: Common stock options and warrants 1,378,503 - Total shares for purpose of calculating diluted net loss per common share 98,047,503 102,897 Net loss per common share: Basic $ - $ - Diluted $ - $ -

2. Summary of Significant Acc49

2. Summary of Significant Accounting Policies: Net Loss Per Common Share: Schedule of common stock equivalents (Tables)	12 Months Ended
	Sep. 30, 2016
Tables/Schedules
Schedule of common stock equivalents	2016 2015 Common stock options and warrants 14,970,587 9,497,551 Series D convertible preferred stock 225,000 225,000 Series E convertible preferred stock 477,834 477,830 Series F convertible preferred stock - 16,065,328 Convertible debt 65,841,342 12,838,412 Restricted shares of common stock 7,500 7,500 Liability to issue common stock 3,692,308 - Total common stock equivalents 85,214,571 39,111,621

3. Discontinued Operations_ Sch

3. Discontinued Operations: Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures (Tables)	12 Months Ended
	Sep. 30, 2016
Tables/Schedules
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures	2016 2015 Revenues $ - $ 152,686 Cost of revenues - 127,709 Gross profit - 24,977 Selling, general and administrative expenses - (211,209 ) Loss from discontinued operations $ - (186,232 )

4. Prepaid Expenses and Other51

4. Prepaid Expenses and Other Current Assets: Schedule of Other Current Assets (Tables)	12 Months Ended
	Sep. 30, 2016
Tables/Schedules
Schedule of Other Current Assets	2016 2015 Prepaid legal and professional fees $ 333,741 $ 2,500 Other 112,117 8,661 Research and development 96,346 - Prepaid information technology services 57,073 9,810 Line of credit acquisition fees 30,978 - Prepaid insurance 14,602 5,942 Prepaid consulting services - 291,648 Prepaid employee services - 205,000 Total prepaid expenses and other current assets $ 644,857 $ 523,561

6. Property, Plant and Equipm52

6. Property, Plant and Equipment Disclosure: Schedule of Property and Equipment (Tables)	12 Months Ended
	Sep. 30, 2016
Tables/Schedules
Schedule of Property and Equipment	2016 2015 Software $ 47,974 $ 100,574 Leasehold improvements 98,023 98,023 Furniture 68,758 68,758 Equipment 49,772 59,754 Total property and equipment 264,527 327,109 Accumulated depreciation and amortization (177,793 ) (191,339 ) Property and equipment, net $ 86,734 $ 135,770

8. Accrued Expenses_ Schedule o

8. Accrued Expenses: Schedule of Accrued Expenses (Tables)	12 Months Ended
	Sep. 30, 2016
Tables/Schedules
Schedule of Accrued Expenses	2016 2015 Interest $ 1,206,387 $ 190,045 Liability to issue common stock 240,000 40,000 Payroll expense 207,052 270,974 Warranty liability 134,330 - Deferred revenue 111,803 147,344 Other 89,828 31,172 Severance 60,000 - Commissions and fees 52,311 64,432 Total accrued expenses $ 2,101,711 $ 743,967

9. Notes Payable_ Schedule of D

9. Notes Payable: Schedule of Debt (Tables)	12 Months Ended
	Sep. 30, 2016
Tables/Schedules
Schedule of Debt	2016 2015 Unsecured notes payable with interest at 10% per annum, due November 2018. The notes may go into default in the event other notes payable go into default subsequent to the effective date of the note. In February 2016, the Company redeemed all 5,361 shares of its Series F Convertible Preferred Stock ("Series F preferred") plus accrued dividends of $673,948 for 10,000,000 shares of common stock with a fair value of $1,600,000 containing certain temporary restrictions, and $5,900,000 of notes payable. Payments on the notes are partially or fully convertible at the Company's option at $0.30 per share to a maximum of 19,667,000 shares of common stock. The conversion rate is adjustable to any lower rates granted through equity sales or other conversion rates provided by issuances of other debt, warrants, options or other instruments, with the exception of certain other raises. A note may only be converted if the holder owns less than 4.99% of the Company’s common stock after conversion. The Company recorded a derivative liability of $2,461,899 related to the conversion feature of the notes. In connection with the redemption of the Series F preferred stock, the Company issued new warrants in exchange for warrants held by the Series F preferred stockholders for the purchase of 5,534,097 shares of common stock at an exercise price of $0.30 per common share, adjustable to any lower rates granted through equity sales or other conversion rates provided by issuances of other debt, warrants, options or other instruments, with the exception of certain other raises. The Company is also required to issue additional warrants for the purchase of up to 16,000 shares of common stock exercisable at $0.001 per share, also adjustable, that vest upon certain events of default. The fair value of $1,344,608 related to the new warrants was recorded as a derivative (see Notes 16 and 19). The fair value of the stock, conversion feature, warrants and $25,000 of fees, in excess of the carrying value of the Series F preferred stock were recorded as a deemed dividend of $6,484,236. Subsequent to September 30, 2016, the Company entered into letter agreements related to the note to convert the outstanding principal and interest into shares of common stock contingent upon a public offering proposed on Form S-1 originally filed with the SEC on July 19, 2016 (the “offering”) (see Note 21). $ 5,900,000 $ - Unsecured note payable with a vendor with interest at 0.65% per annum, due January 2018, issued in March 2016 upon the conversion of $2,523,937 in accounts payable to the vendor. $ 2,223,937 $ - Secured note payable to a third party with interest at 12.75% per annum, due February 2019. The note is secured by the assets of the Company and may go into default in the event other notes payable go into default subsequent to the effective date of the note. The Company entered into the note payable agreement in conjunction with a line of credit. The Company initially borrowed $1,500,000 and may borrow additional amounts under the note payable agreement up to a total balance of $3,000,000 as the Company meets certain milestones. The interest rate may also reduce to 11.25% per annum as the Company meets certain milestones. In conjunction with the note and related line of credit, the Company issued warrants to the lender to purchase 12,015,350 shares of common stock at $0.065 per share with a fair market value of $3,732,100 (see Notes 16 and 19), which resulted in a loss on derivative of $2,309,461. The Company has recorded discounts of $1,500,000, which are being amortized to interest expense over the term of the note. In April 2016, the Company borrowed an additional $500,000 on the note and incurred additional fees of $25,000, which are being amortized to interest expense over the remaining term of the note. Subsequent to September 30, 2016, the Company entered into forbearance agreements related to the note (see Note 21). 1,652,778 - Secured line of credit with a third party with interest at 12.25% per annum, due February 2018. The note is secured by the assets of the Company and may go into default in the event other notes payable go into default subsequent to the effective date of the note. The Company entered into the line of credit agreement in conjunction with a note payable. The Company may draw up to the lesser of 80% of certain accounts receivable or $1,500,000 and increase the maximum it may borrow under the agreement up to a total balance of $3,000,000 at $500,000 per increase as the Company meets certain milestones. The interest rate may also reduce to 10.75% per annum as the Company meets certain milestones. In conjunction with the line of credit and related note, the Company issued warrants to purchase 12,015,350 shares of common stock at $0.065 per share with a fair market value of $3,732,100 (see Notes 16 and 19), which resulted in a loss on derivative of $2,309,461. The Company has recorded prepaid expenses of $44,665, which are being amortized to interest expense over the term of the line of credit. 929,518 - Secured borrowings from a third party that purchased $1,658,000 of customer receivables for $1,230,000, with due dates ranging from September 2016 to April 2017, and payable in daily payments ranging from $2,454 to $3,996. The $269,000 difference between the customer receivables and cash received is being amortized to interest expense over the term of the respective notes. The secured borrowings are guaranteed by two officers of the Company and are subordinated to other notes payable. 689,318 - Unsecured note payable with a third party with no interest, due the earlier of November 2016 or the third business day after the closing of a proposed offering on Form S-1 filed on July 19, 2016. Pursuant to the note, the Company may borrow up to $1,500,000 upon meeting certain milestones. The note requires a payment of common stock on the 5th trading day after the pricing of the proposed offering, but no later than December 15, 2016. The number of common shares will equal $200,000 divided by the lowest of (i) the lowest daily closing price of the common stock during the ten days prior to delivery of the common shares or during the ten days prior to the date of the Purchase Agreement, (ii) 80% of the common stock offering price of the offering, (iii) 80% of the unit price offering price of the offering, or (iv) the exercise price of any warrants issued in the offering. The estimated fair value of $240,000 of the stock is included in accrued liabilities and is being amortized to interest expense over the life of the note. In connection with the issuance of the note, the Company also issued 10,000,000 warrants to purchase shares of common stock at an exercise price per share equal to the lesser of (i) 80% of the per share price of the common stock in the offering, (ii) $0.05 per share, (iii) 80% of the unit price in the offering, or (iv) the exercise price of any warrants issued in the offering and the number of shares will reset upon the closing of the offering. The warrants may only be exercised to the extent the holder would own a maximum of 9.99% of the Company’s common stock after exercise. The fair value of $493,590 related to the new warrants was recorded as a derivative (see Notes 16 and 19). Of this fair value amount, $220,000 was recorded as a debt discount and is being amortized over the life of the note and the remaining $273,590 was recorded as a loss on derivative liability. In the event of borrowing in excess of an initial $500,000, the Company will be required to issue additional warrants with an aggregate exercise amount equal to 100% of the additional amount borrowed with similar terms to the initial warrants issued. Subsequent to September 30, 2016, the Company borrowed the remaining $1,000,000 on the note and extended the maturity date (see Note 21). $ 500,000 $ - Note payable previously secured by CareServices customer contracts. In January 2015, the note was amended to reduce the outstanding principal to $375,000, interest at 9% per annum, and payable in 15 monthly installments beginning in February 2015. The amendment released the collateralized customer contracts and the note payable is guaranteed by both a former Executive Chairman of the Board of Directors and a member of the Board of Directors. A gain on the extinguishment of the old note of $769,449 was recorded in other income. In December 2015, the note was amended to extend maturity to January 2018 payable in monthly installments beginning in July 2016, convert $31,252 from accrued interest into principal, interest at 10% per annum, and provide that the note is convertible into common stock at its fair value per share. The Company recorded a derivative in connection with the convertible feature of the note (see Note 16) and is amortizing the initial $302,690 fair value of the derivative liability over the life of the note. In February 2016, the note was amended to subordinate to other notes payable also issued during February 2016. In July 2016, the note was amended to extend the maturity date to the earlier of an equity raise in excess of $10,000,000 or November 2016 and included additional default penalties and payment terms. In October 2016, the note was amended to extend the maturity date to the earlier of an equity raise in excess of $10,000,000 or February 15, 2017 and included additional default penalties and payment terms. 334,464 303,212 Unsecured note payable with interest at 12% per annum, due February 2016, convertible into common stock at $0.30 per share. In connection with the issuance of the note, the Company repriced previously issued warrants to purchase shares of common stock. The $22,397 increase in relative fair value of the warrants was included as a loss on the extinguishment of the old note in other expense in fiscal 2015. The note also required a payment of 3,000,000 shares of common stock. The fair value of $780,000 was included as a loss on the extinguishment of the old note in other expense in fiscal 2015. The maturity date was subsequently extended on two occasions for a total of 250,000 shares of common stock and the note was due May 2016. The $31,250 fair value of these shares was being amortized over the extension period. In February 2016, the note was amended to subordinate to other notes payable also issued during February 2016, and the conversion price was reduced to $0.06 per share, which was below the fair value of the Company’s common stock on the date of the amendment. The note may only be converted if the holder owns less than 9.99% of the Company’s common stock after conversion. The Company recorded the value of the beneficial conversion feature of $381,299 to loss on termination of debt as a result of the modification. In May 2016, the note was amended to extend the maturity date to the earlier of an equity raise of $10,000,000 or October 2016 which required a payment of 300,000 shares of common stock. The $28,500 fair value of these shares has been included in accrued liabilities and is being amortized over the extension period. Subsequent to September 30, 2016, the Company extended the maturity date of the note month-by-month through no later than April 30, 2017 for a fee of $5,000 per month extended (see Note 21). $ 300,000 $ 300,000 Unsecured note payable with interest at 12% per annum, due September 2016, subordinated to other notes payable. In connection with the issuance of the note, the Company issued 1,000,000 shares of common stock. The $100,000 fair value of the stock is being amortized to interest expense over the term of the note. Subsequent to September 30, 2016, the Company entered into a letter agreement related to the note to convert the outstanding principal and interest into shares of common stock contingent upon the completion of the offering (see Note 21). 250,000 - Secured note payable to a third party with interest at 18% per annum, due June 2017. The note is secured by shares of the Company's common stock held by, and other assets of an entity controlled by, a former Executive Chairman of the Board of Directors. The note is guaranteed by a former Executive Chairman of the Board of Directors and his related entity and may go into default in the event other notes payable go into default subsequent to the effective date of the note. Payments on the note are convertible at the holder's option into common stock at 75% of its fair value if not paid by its respective due date, which is subject to a 20 trading day true-up and is adjustable to any lower rates granted through equity sales or other conversion rates provided by issuances of other debt, warrants, options or other instruments, with the exception of other certain raises. The note may only be converted if the holder owns less than 4.99% of the Company’s common stock after conversion. The Company recognized a derivative liability related to the conversion feature with a fair value of $181,670, which was recognized as a loss on termination of debt. In June 2016, $13,713 of principal and $11,287 of accrued interest converted into 476,190 shares of common stock, pursuant to the terms of the note. In August 2016, $64,654 of principal and $10,346 of accrued interest converted into 4,601,226 shares of common stock, pursuant to the terms of the note. The note was terminated subsequent to September 30, 2016 (see Note 21). 162,539 - Unsecured notes with interest at 18% per annum, due April 2013, in default. The Company issued 20,000 shares of Series D preferred stock as loan origination fees. The $195,000 fair value of the preferred stock was amortized over the original term of the note. Principal of $50,000 and accrued interest of $13,333 were converted to common stock in December 2013. Subsequent to September 30, 2016, the Company entered into a letter agreement related to the remainder of the note to convert the outstanding principal and interest into shares of common stock contingent upon the completion of the offering (see Note 21). $ 64,261 $ 64,261 Secured borrowings from a third party that purchased $945,000 of customer receivables for $750,000, with due dates ranging from November 2015 to December 2016, payable in daily payments ranging from $955 to $1,909. The $195,000 difference between the customer receivables and cash received is being amortized to interest expense over the term of the respective notes. The secured borrowings are guaranteed by two officers of the Company. In November 2015, one of the notes was amended to subordinate to another note and to increase the principal by $28,385. The additional principal amount is being amortized to interest expense over the term of the note. In February 2016, the remaining principal balance on the borrowings of $417,160 was settled for a cash payment of $377,607, or 91% of the then outstanding balance, which resulted in a loss on termination of debt of $61,319. - 421,413 Secured borrowings from third parties that purchased a $337,600 customer receivable for $200,000. The Company repurchased the receivable for $233,333 less cash received by the third parties before June 2015. The $33,333 difference between the buyback and cash received, plus $20,000 of fees paid to a related party, was amortized to interest expense through June 2015. In February 2016, the notes were converted into 5,800,000 shares of common stock, at $0.04 per share, which was below the fair value of the Company’s stock on the date of conversion, which resulted in a loss on induced conversion of debt of $230,667. - 233,333 Unsecured notes payable with interest at 12% per annum, with due dates ranging from March 2016 to April 2016, convertible into common stock at a 15% discount from the 10-day volume adjusted weighted average closing price per share upon maturity. In connection with the issuance of the notes, the Company also issued 841,176 shares of common stock as an origination fee. The $119,205 fair value of the stock is being amortized to interest expense over the term of the notes. The notes included loan origination fees of $35,049, which are being amortized to interest expense over the term of the notes. The Company recorded a derivative liability in connection with the convertible feature of the notes (see Note 16) and is amortizing the initial $151,283 fair value of the derivatives liability over the life of the notes. In February 2016, the notes with outstanding principal balances totaling $350,490 plus accrued interest of $15,629 were converted into 9,287,985 shares of common stock at $0.04 per share, which was below the fair value of the Company’s stock on the date of conversion. The Company recognized a loss on induced conversion of debt of $148,465 and a gain on termination of debt of $64,099 in relation to the conversion. $ - $ 212,490 Total notes payable before discount 13,006,815 1,534,709 Less discount (1,930,060 ) (274,793 ) Total notes payable 11,076,755 1,259,916 Less current portion (3,722,899 ) (1,259,916 ) Notes payable, net of current portion $ 7,353,856 $ -

9. Notes Payable_ Schedule of p

9. Notes Payable: Schedule of principal payments on notes payable (Tables)	12 Months Ended
	Sep. 30, 2016
Tables/Schedules
Schedule of principal payments on notes payable	Year Ending September 30, 2017 $ 4,946,767 2018 2,003,895 2019 6,056,153

10. Related-party Notes Payab56

10. Related-party Notes Payable: Schedule of related party notes payable (Tables)	12 Months Ended
	Sep. 30, 2016
Tables/Schedules
Schedule of related party notes payable	2016 2015 Secured borrowings from entities controlled by an officer who purchased a $2,813,175 customer receivable for $1,710,500. The Company repurchased the receivable for $1,950,000 less cash received by the entities through March 2015. The $239,500 difference between the buyback and cash received plus $253,500 of loan origination fees was amortized to interest expense through March 2015. In September 2015, the note was modified to extend the maturity date to January 2017, with interest at 18% per annum. The Company added $81,600 of extension fees and issued 3,000,000 shares of common stock to a lender as part of the modification. The note is convertible into common stock at $0.30 per share. The $540,000 fair value of the common stock was recognized as a loss on extinguishment of debt in fiscal 2015. In February 2016, the note was amended to subordinate to other notes payable also issued during February 2016, and the conversion price was reduced to $0.06 per share, which was below the fair value of the Company’s stock on the date of the amendment. The conversion of the note is now limited to a maximum of 20,000,000 common shares in combination with other convertible notes payable held by the lenders. The note has a default penalty of 4,203,389 shares of common stock, in combination with other convertible notes held by the lenders, if not paid by maturity. The Company recorded the value of the combined beneficial conversion features of $1,400,000 to loss on termination of debt as a result of the amendment. Subsequent to September 30, 2016, the Company entered into a letter agreement related to the secured borrowings to convert the outstanding principal and interest into shares of common stock contingent upon the completion of the offering (see Note 21). $ 1,721,100 $ 1,721,100 Unsecured note payable to an entity controlled by an officer with interest at 18% per annum, due January 2017, convertible into common stock at $0.30 per share. The Company issued 3,000,000 shares of common stock to a lender as loan origination fees. The $540,000 fair value of the common stock was recognized as a loss on extinguishment of debt in fiscal 2015. In February 2016, the note was amended to subordinate to other notes payable also issued during February 2016, and reduced the conversion price to $0.06 per share, which was below the fair value of the Company’s stock on the date of the amendment. The conversion of the note is now limited to a maximum of 20,000,000 common shares in combination with other convertible notes payable held by the lender. The note has a default penalty of 4,203,389 shares of common stock, in combination with other convertible notes held by the lender, if not paid by maturity. The Company recorded the value of the combined beneficial conversion features of $1,400,000 to loss on termination of debt as a result of the amendment. Subsequent to September 30, 2016, the Company entered into a letter agreement related to the note to convert the outstanding principal and interest into shares of common stock contingent upon the completion of the offering (see Note 21). 1,303,135 1,303,135 Unsecured note payable to an entity controlled by a former Executive Chairman of the Board of Directors with interest at 18% per annum, due January 2017. In February 2016, notes payable to the same entity, with outstanding balances of $511,005 plus accrued interest of $30,999 combined into this note. The note is subordinated to notes payable to unrelated parties and is convertible into shares of common stock at $0.06 per share, which was below the fair value of the Company’s stock on the date of the agreement. The conversion of the note is limited to a maximum of 9,250,000 common shares. The Company recorded the value of the beneficial conversion feature of $632,339 to loss on termination of debt. The note has a default penalty of 734,489 shares of common stock if not paid by maturity. The note may only be converted if the holder owns less than 4.99% of the Company’s common stock after conversion. Subsequent to September 30, 2016, the Company entered into a letter agreement related to the note to convert the outstanding principal and interest into shares of common stock contingent upon the completion of the offering (see Note 21). $ 542,004 $ - Unsecured note payable to an entity controlled by an officer with interest at 12% per annum, due September 2016, subordinated to other third party notes payable. In connection with the issuance of the note, the Company issued 1,000,000 shares of common stock. The $70,000 fair value of the stock is being amortized to interest expense over the term of the note. Subsequent to September 30, 2016, the Company entered into a letter agreement related to the note to convert the outstanding principal and interest into shares of common stock contingent upon the completion of the offering (see Note 21). 250,000 - Unsecured note payable to a former officer with interest at 12% per annum, due September 2013. This note is in default and is convertible into common stock at $0.75 per share. 26,721 26,721 Unsecured note payable to an entity controlled by an officer with interest at 18% per annum, due on demand. In February 2016, the note was amended to subordinate the note to other notes payable also issued during February 2016. The note is convertible into shares of common stock at $0.06 per share, which was below the fair value of the Company’s stock on the date of the amendment. The conversion of the note is now limited to a maximum of 20,000,000 common shares in combination with other convertible notes payable held by the entity. The note has a default penalty of 4,203,389 shares of common stock, in combination with other convertible notes held by the entity, if not paid by maturity. The Company recorded the value of the combined beneficial conversion features of $1,400,000 to loss on termination of debt as a result of the amendment. 25,463 25,463 Unsecured note payable to a former officer with interest at 15% per annum, due June 2012, in default. The note included a $3,000 loan origination fee added to the principal and is convertible into common stock at $0.50 per share. 17,227 30,000 Unsecured note payable to a former officer with interest at 12% per annum, due on demand. 12,474 13,644 Unsecured note payable to an entity controlled by a former Executive Chairman of the Board of Directors with no interest (18% per annum in the event of default), due on demand. The holder demanded payment by May 15, 2015. In February 2016, the note with an outstanding balance of $396,667 plus accrued interest of $53,403 was bifurcated into two notes payable of $243,082 and $206,988. The $243,082 bifurcated note plus $20,000 of the second bifurcated note was assigned to a third party and converted into a convertible note payable. The remaining $186,989 portion of the second bifurcated note, plus $3,521 of accrued interest, in combination with another note payable held by the entity in the amount of $324,016 plus $27,478 of related accrued interest, were converted into a convertible note payable of $542,004. $ - $ 396,667 Unsecured note payable to an entity controlled by a former Executive Chairman of the Board of Directors with interest at 18% per annum, due January 2017. In February 2016, the note with an outstanding balance of $324,016 plus accrued interest of $27,478, in combination with another note payable held by the entity of $186,989 plus $3,521 of accrued interest, were converted into a convertible note payable of $542,004. - 324,016 Total notes payable, related-party 3,898,124 3,840,746 Less current portion (3,898,124 ) (492,495 Notes payable, related-party, net of current portion $ - $ 3,348,251

10. Related-party Notes Payab57

10. Related-party Notes Payable: Schedule of Principal Payments on Notes Payable, Related Parties (Tables)	12 Months Ended
	Sep. 30, 2016
Tables/Schedules
Schedule of Principal Payments on Notes Payable, Related Parties	Year Ending September 30, 2017 $ 3,898,124

12. Fair Value Measurements_ Fa

12. Fair Value Measurements: Fair Value, Liabilities Measured on Recurring Basis (Tables)	12 Months Ended
	Sep. 30, 2016
Tables/Schedules
Fair Value, Liabilities Measured on Recurring Basis	Quoted Prices in Active Markets for Identical Items (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total September 30, 2016 Derivatives liability $ - $ 281,613 $ 1,772,458 $ 2,054,071 September 30, 2015 Derivatives liability - 79,347 - 79,347

12. Fair Value Measurements_ 59

12. Fair Value Measurements: Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation (Tables)	12 Months Ended
	Sep. 30, 2016
Tables/Schedules
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation	Derivatives Liability Balance, September 30, 2015 $ - Issuance of warrants recorded as derivatives 5,570,167 Issuance of embedded derivatives related to notes payable 2,643,569 Gain on derivatives liability resulting from changes in fair value (6,441,278 ) Balance, September 30, 2016 $ 1,772,458

16. Common Stock Options and 60

16. Common Stock Options and Warrants: Schedule of fair value assumptions (Tables)	12 Months Ended
	Sep. 30, 2016
Tables/Schedules
Schedule of fair value assumptions	2016 2015 Exercise price $0.30 $0.30 - $1.00 Expected term (years) 5 1 - 2 Volatility 219% 228% - 302% Risk-free rate 1.57% 0.22%- 0.63% Dividend rate 0% 0%

16. Common Stock Options and 61

16. Common Stock Options and Warrants: Schedule of Share Based Payment Award Stock Options Valuation Assumptions, Level 3 (Tables)	12 Months Ended
	Sep. 30, 2016
Tables/Schedules
Schedule of Share Based Payment Award Stock Options Valuation Assumptions, Level 3	Exercise price $0.02 - $[A1] 0.30[A2] Expected term (years) 4.09 – [A3] 6.40 Volatility 134% - 189% Risk-free rate 0.91% - 1.44% Dividend rate 0% Common stock price $0.02 - $0.40

16. Common Stock Options and 62

16. Common Stock Options and Warrants: Schedule of Share-based Compensation, Activity (Tables)	12 Months Ended
	Sep. 30, 2016
Tables/Schedules
Schedule of Share-based Compensation, Activity	Options and Warrants Number of Options and Warrants Weighted- Average Exercise Price Outstanding as of October 1, 2015 9,497,551 $ 0.91 Granted 28,882,780 0.07 Cancelled (326,200 ) 0.81 Forfeited (5,534,097 ) 1.10 Outstanding as of September 30, 2016 32,520,037 0.13 Exercisable as of September 30, 2016 28,015,034 0.11

17. Segment Information_ Schedu

17. Segment Information: Schedule of Segment Reporting Information, by Segment (Tables)	12 Months Ended
	Sep. 30, 2016
Tables/Schedules
Schedule of Segment Reporting Information, by Segment	Corporate Chronic Illness Monitoring CareServices (Discontinued Operations) Total As of September 30, 2016 and for the Fiscal Year Then Ended: Sales to external customers $ - $ 7,464,146 $ - $ 7,464,146 Segment income (loss) (10,151,704 ) 1,029,144 - (9,122,560 ) Interest expense, net 2,963,747 - - 2,963,747 Segment assets 926,469 691,737 - 1,618,206 Property and equipment purchases 5,004 - - 5,004 Depreciation and amortization 51,376 - - 51,376 As of September 30, 2015 and for the Fiscal Year Then Ended: Sales to external customers $ - $ 6,597,981 $ 152,686 $ 6,750,667 Segment loss (10,757,547 ) (583,890 ) (186,232 ) (11,527,669 ) Interest expense, net 977,234 - - 977,234 Segment assets 767,302 1,771,658 - 2,538,960 Property and equipment purchases 15,289 - - 15,289 Depreciation and amortization 57,036 - 233,664 290,700

18. Income Taxes_ Schedule of D

18. Income Taxes: Schedule of Deferred Tax Assets and Liabilities (Tables)	12 Months Ended
	Sep. 30, 2016
Tables/Schedules
Schedule of Deferred Tax Assets and Liabilities	2016 2015 Net operating loss carryforwards $ 33,307,000 $ 29,000,000 Depreciation, amortization and reserves 442,000 721,000 Stock-based compensation 1,619,000 1,728,000 Accrued vacation 23,000 28,000 Valuation allowance (35,391,000 ) (31,477,000 ) Total $ - $ -

18. Income Taxes_ Schedule of C

18. Income Taxes: Schedule of Components of Income Tax Expense (Benefit) (Tables)	12 Months Ended
	Sep. 30, 2016
Tables/Schedules
Schedule of Components of Income Tax Expense (Benefit)	2016 2015 Federal income tax benefit at statutory rate $ 3,102,000 $ 3,919,000 State income tax benefit, net of federal income tax effect 300,000 380,000 Permanent differences 498,000 (367,000 ) Other 14,000 112,000 Change in valuation allowance (3,914,000 ) (4,044,000 ) Benefit for income taxes $ - $ -

19. Commitments and Contingen66

19. Commitments and Contingencies: Schedule of Future Minimum Rental Payments for Operating Leases (Tables)	12 Months Ended
	Sep. 30, 2016
Tables/Schedules
Schedule of Future Minimum Rental Payments for Operating Leases	Years Ending September 30, 2017 $ 130,036 2018 111,340 $ 241,376

2. Summary of Significant Acc67

2. Summary of Significant Accounting Policies: Discontinued Operations, Policy (Details) - USD ($)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Loss from discontinued operations		$ 186,232
CareServices
Loss from discontinued operations	$ 0	$ 186,232

2. Summary of Significant Acc68

2. Summary of Significant Accounting Policies: Concentrations of Credit Risk (Details)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Details
Concentration Risk, Customer	the Company had revenues from two significant customers which represented 64% of total revenues	the Company had revenues from three significant customers which represented 69% of total revenues
Concentration Risk, Accounts Receivable	accounts receivable from significant customers represented 66% of total accounts receivable	accounts receivable from significant customers represented 66% of total accounts receivable
Concentration Risk, Vendor	the Company purchased substantially all of its products and supplies from one vendor.	the Company purchased substantially all of its products and supplies from one vendor.

2. Summary of Significant Acc69

2. Summary of Significant Accounting Policies: Accounts Receivable (Details) - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Details
Allowance for Doubtful Accounts Receivable	$ 75,161	$ 30,495

2. Summary of Significant Acc70

2. Summary of Significant Accounting Policies: Inventory: Schedule of Utility Inventory (Details) - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Details
Inventory, Finished Goods, Gross	$ 206,444	$ 206,038
Finished goods held by distributors		1,350,368
Inventory, Gross	206,444	1,556,406
Inventory Valuation Reserves	(1,708)	(813,935)
Inventory	$ 204,736	$ 742,471

2. Summary of Significant Acc71

2. Summary of Significant Accounting Policies: Goodwill (Details)	12 Months Ended
	Sep. 30, 2015USD ($)
Details
Goodwill and Intangible Asset Impairment	$ 825,894

2. Summary of Significant Acc72

2. Summary of Significant Accounting Policies: Research and Development Costs (Details) - USD ($)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Details
Research and development	$ 248,441	$ 106,526

2. Summary of Significant Acc73

2. Summary of Significant Accounting Policies: Advertising Costs (Details) - USD ($)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Details
Advertising Expense	$ 60,295	$ 30,551

2. Summary of Significant Acc74

2. Summary of Significant Accounting Policies: Net Loss Per Common Share: Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Net income (loss), excluding discontinued operations	$ (16,338,456)	$ (12,637,517)
Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities	$ (18,195,526)	$ (12,637,517)
Weighted average common shares outstanding - basic	96,669,000	51,444,000
Weighted average common shares outstanding - diluted	98,047,503	51,444,000
Continuing operations - basic	$ (0.17)	$ (0.25)
Continuing operations - diluted	(0.19)	$ (0.25)
Loss from discontinued operations		$ (186,232)
Discontinued operations - basic	$ 0	$ 0
Discontinued Operations
Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities	$ 98,047,503	$ 102,897
Weighted average common shares outstanding - basic	96,669,000	102,897
Common stock options and warrants
Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities	$ (1,857,070)
Antidilutive Securities Excluded from Computation of Net Income, Per Outstanding Unit, Amount	$ 1,378,503
Common stock options and warrants | Discontinued Operations
Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities	$ 1,378,503

2. Summary of Significant Acc75

2. Summary of Significant Accounting Policies: Net Loss Per Common Share: Schedule of common stock equivalents (Details) - shares	Sep. 30, 2016	Sep. 30, 2015
Details
Common stock options and warrants	14,970,587	9,497,551
Series D convertible preferred stock	225,000	225,000
Series E convertible preferred stock	477,834	477,830
Series F convertible preferred stock		16,065,328
Convertible debt - Shares	65,841,342	12,838,412
Restricted shares of common stock	7,500	7,500
Liability to issue common stock	3,692,308
Total common stock equivalents	85,214,571	39,111,621

3. Discontinued Operations_ S76

3. Discontinued Operations: Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures (Details) - USD ($)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Total Chronic illness monitoring revenues	$ 7,464,146	$ 6,597,981
Chronic illness monitoring supplies cost of revenues	4,876,321	4,669,470
Gross profit	2,129,974	1,401,154
Total operating expenses	$ 8,443,119	10,464,936
Loss from discontinued operations		(186,232)
Discontinued Operations
Total Chronic illness monitoring revenues		152,686
Chronic illness monitoring supplies cost of revenues		127,709
Gross profit		24,977
Total operating expenses		(211,209)
Loss from discontinued operations		$ (186,232)

4. Prepaid Expenses and Other77

4. Prepaid Expenses and Other Current Assets: Schedule of Other Current Assets (Details) - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Prepaid expenses and other	$ 644,857	$ 523,561
Prepaid professional fees
Prepaid expenses and other	333,741	2,500
Other
Prepaid expenses and other	112,117	8,661
Research and Development
Prepaid expenses and other	96,346
Prepaid information technology services
Prepaid expenses and other	57,073	9,810
Line of credit acquisition fees
Prepaid expenses and other	30,978
Prepaid insurance
Prepaid expenses and other	$ 14,602	5,942
Prepaid consulting services
Prepaid expenses and other		291,648
Prepaid employee services
Prepaid expenses and other		$ 205,000

5. Customer Contracts (Details)

5. Customer Contracts (Details) - USD ($)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Customer Contracts | CareServices
Amortization of Intangible Assets	$ 0	$ 179,648

6. Property, Plant and Equipm79

6. Property, Plant and Equipment Disclosure: Schedule of Property and Equipment (Details) - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Property, Plant and Equipment, Gross	$ 264,527	$ 327,109
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	(177,793)	(191,339)
Property and equipment, net	86,734	135,770
Software and Software Development Costs
Property, Plant and Equipment, Gross	47,974	100,574
Leasehold Improvements
Property, Plant and Equipment, Gross	98,023	98,023
Furniture and Fixtures
Property, Plant and Equipment, Gross	68,758	68,758
Equipment
Property, Plant and Equipment, Gross	$ 49,772	$ 59,754

6. Property, Plant and Equipm80

6. Property, Plant and Equipment Disclosure (Details) - USD ($)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Details
Loss on disposal of property and equipment	$ 2,780	$ 42,336
Depreciation, Amortization and Accretion, Net	$ 50,661	$ 56,321

7. Patents (Details)

7. Patents (Details) - USD ($)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2012
Common stock shares issued in purchase of patents			600,000
Series C stock shares issued in purchase of patents			480,000
Independent valuation of patents			$ 922,378
Value of the Common Stock issued			240,000
Value of the Series C Preferred Stock issued			$ 682,378
Patents
Amortization of Intangible Assets	$ 0	$ 31,718
Cost Associated with Intangible Assets	$ 514,046	$ 514,046

8. Accrued Expenses_ Schedule82

8. Accrued Expenses: Schedule of Accrued Expenses (Details) - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Accrued expenses	$ 2,101,711	$ 743,967
Interest Expense
Accrued expenses	1,206,387	190,045
Liability To Issue Common Stock
Accrued expenses	240,000	40,000
Payroll Expense
Accrued expenses	207,052	270,974
Warranty Liability
Accrued expenses	134,330
DeferredRevenueMember
Accrued expenses	111,803	147,344
Other Expense
Accrued expenses	89,828	31,172
Severance
Accrued expenses	60,000
CommissionsAndFeesMember
Accrued expenses	$ 52,311	$ 64,432

9. Notes Payable_ Schedule of83

9. Notes Payable: Schedule of Debt (Details) - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Gross notes payable before discount	$ 13,006,815	$ 1,534,709
Discount on notes payable	(1,930,060)	(274,793)
Notes payable current and noncurrent	11,076,755	1,259,916
Notes payable current portion	(3,722,899)	(1,259,916)
Notes payable, net of current portion	7,353,856
Note 1
Gross notes payable before discount	5,900,000
Note 2
Gross notes payable before discount	2,223,937
Note 3
Gross notes payable before discount	1,652,778
Note 4
Gross notes payable before discount	929,518
Note 5
Gross notes payable before discount	689,318
Note 6
Gross notes payable before discount	500,000
Note 7
Gross notes payable before discount	334,464	303,212
Note 8
Gross notes payable before discount	300,000	300,000
Note 9
Gross notes payable before discount	250,000
Note 10
Gross notes payable before discount	162,539
Note 11
Gross notes payable before discount	$ 64,261	64,261
Note 12
Gross notes payable before discount		421,413
Note 13
Gross notes payable before discount		233,333
Note14Member
Gross notes payable before discount		$ 212,490

9. Notes Payable_ Schedule of84

9. Notes Payable: Schedule of principal payments on notes payable (Details)	12 Months Ended
	Sep. 30, 2016USD ($)
Details
Notes payable principal payments in 2017	$ 4,946,767
Notes payable principal payments in 2018	2,003,895
Notes payable principal payments in 2019	$ 6,056,153

10. Related-party Notes Payab85

10. Related-party Notes Payable: Schedule of related party notes payable (Details) - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Gross notes payable related party before discount	$ 3,898,124	$ 3,840,746
Current portion of notes payable, related party	(3,898,124)	(492,495)
Notes payable, related party, net of current portion		3,348,251
Note 1
Gross notes payable related party before discount	1,721,100	1,721,100
Note 2
Gross notes payable related party before discount	1,303,135	1,303,135
Note 3
Gross notes payable related party before discount	542,004
Note 4
Gross notes payable related party before discount	250,000
Note 5
Gross notes payable related party before discount	26,721	26,721
Note 6
Gross notes payable related party before discount	25,463	25,463
Note 7
Gross notes payable related party before discount	17,227	30,000
Note 8
Gross notes payable related party before discount	$ 12,474	13,644
Note 9
Gross notes payable related party before discount		396,667
Note 10
Gross notes payable related party before discount		$ 324,016

10. Related-party Notes Payab86

10. Related-party Notes Payable: Schedule of Principal Payments on Notes Payable, Related Parties (Details)	12 Months Ended
	Sep. 30, 2016USD ($)
Details
Notes payable - related party principal payments in 2017	$ 3,898,124

12. Fair Value Measurements_ 87

12. Fair Value Measurements: Fair Value, Liabilities Measured on Recurring Basis (Details) - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Derivatives liability	$ 2,054,071	$ 79,347
Fair Value, Inputs, Level 2
Derivatives liability	281,613	$ 79,347
Fair Value, Inputs, Level 3
Derivatives liability	$ 1,772,458

12. Fair Value Measurements_ 88

12. Fair Value Measurements: Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation (Details) - USD ($)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Derivatives liability	$ 2,054,071	$ 79,347
Fair Value, Inputs, Level 3
Issuance of warrants recorded as derivative	5,570,167
Issuance of embedded derivatives related to notes payable	2,643,569
Loss (gain) on derivative liability resulting from changes in fair value	(6,441,278)
Derivatives liability	$ 1,772,458

13. Derivatives Liability (Deta

13. Derivatives Liability (Details) - USD ($)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Details
Derivatives liability	$ 2,054,071	$ 79,347
Gain on derivatives liability	$ 3,405,035	$ 128,942

14. Preferred Stock (Details)

14. Preferred Stock (Details) - USD ($)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2014
Preferred stock shares authorized	10,000,000	10,000,000
Preferred stock par value	$ 0.00001	$ 0.00001
Dividends payable	$ 606,545	$ 567,350
Represents the monetary amount of IssuanceOfSeriesEPreferredStockForDebtConversions, during the indicated time period.		83,473
Redemption Price of Series E preferred stock	477,829	477,829
Represents the monetary amount of IssuanceOfSeriesFPreferredStockForCashNet, during the indicated time period.		3,580,771
Related Costs Considered in Conversion of Series F Preferred Stock		675,229
Represents the monetary amount of IssuanceOfSeriesFPreferredStockForDebtConversions, during the indicated time period.		574,592
Series D Preferred Stock
Dividends payable	$ 18,617	$ 24,800
Common Stock issued to settle accrued dividends	302,517	118,068
Series E Preferred Stock
Dividends payable	$ 217,895	$ 326,863
Represents the IssuanceOfSeriesEPreferredStockForDebtConversionsShares (number of shares), during the indicated time period.		8,347
Series F Preferred Stock
Dividends payable	$ 495,148	$ 643,320
Common Stock issued to settle accrued dividends	3,372,917
Convertible Preferred Stock Shares Designated			7,803
Represents the IssuanceOfSeriesFPreferredStockForDebtConversionsShares (number of shares), during the indicated time period.		858
Represents the IssuanceOfSeriesFPreferredStockForCashNetShares (number of shares), during the indicated time period.		4,503

15. Common Stock (Details)

15. Common Stock (Details) - USD ($)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Common stock shares authorized	200,000,000	200,000,000
Option1Member
Stock Granted, Value, Share-based Compensation, Net of Forfeitures	$ 1,666,710
Option2Member
Stock Granted, Value, Share-based Compensation, Net of Forfeitures	39,063
Option3Member
Stock Granted, Value, Share-based Compensation, Net of Forfeitures	235,100
Option4Member
Stock Granted, Value, Share-based Compensation, Net of Forfeitures	1,600,000
Option5Member
Stock Granted, Value, Share-based Compensation, Net of Forfeitures	229,558
Option6Member
Stock Granted, Value, Share-based Compensation, Net of Forfeitures	121,250
Option7Member
Stock Granted, Value, Share-based Compensation, Net of Forfeitures	70,000
Option8Member
Stock Granted, Value, Share-based Compensation, Net of Forfeitures	31,250
Option9Member
Stock Granted, Value, Share-based Compensation, Net of Forfeitures	$ 18,617
Common stock
Issuance of common stock for services - shares	2,858,047	22,047,659
Common stock | Option1Member
Issuance of common stock for services - shares	20,165,401
Common stock | Option2Member
Issuance of common stock for services - shares	1,008,047
Common stock | Option3Member
Issuance of common stock for services - shares	1,850,000
Common stock | Option4Member
Issuance of common stock for services - shares	10,000,000
Common stock | Option5Member
Issuance of common stock for services - shares	2,422,866
Common stock | Option6Member
Issuance of common stock for services - shares	1,041,666
Common stock | Option7Member
Issuance of common stock for services - shares	1,000,000
Common stock | Option8Member
Issuance of common stock for services - shares	250,000
Common stock | Option9Member
Issuance of common stock for services - shares	302,517

16. Common Stock Options and 92

16. Common Stock Options and Warrants: Schedule of fair value assumptions (Details) - $ / shares	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Maximum
Fair Value Assumptions, Exercise Price	$ 0.30	$ 1
Fair Value Assumptions, Expected Term	5 years	2 years
Fair Value Assumptions, Expected Volatility Rate	219.00%	302.00%
Fair Value Assumptions, Risk Free Interest Rate	1.57%	0.63%
Minimum
Fair Value Assumptions, Exercise Price		$ 0.30
Fair Value Assumptions, Expected Term		1 year
Fair Value Assumptions, Expected Volatility Rate		228.00%
Fair Value Assumptions, Risk Free Interest Rate		0.22%

16. Common Stock Options and 93

16. Common Stock Options and Warrants: Schedule of Share Based Payment Award Stock Options Valuation Assumptions, Level 3 (Details) - $ / shares	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Minimum
Fair Value Assumptions, Exercise Price		$ 0.30
Fair Value Assumptions, Expected Term		1 year
Fair Value Assumptions, Expected Volatility Rate		228.00%
Fair Value Assumptions, Risk Free Interest Rate		0.22%
Minimum | Fair Value, Inputs, Level 3
Fair Value Assumptions, Exercise Price	$ 0.02
Fair Value Assumptions, Expected Term	4 years 1 month 2 days
Fair Value Assumptions, Expected Volatility Rate	134.00%
Fair Value Assumptions, Risk Free Interest Rate	0.91%
Fair Value Assumptions Common Stock Price	$ 0.02
Maximum
Fair Value Assumptions, Exercise Price	$ 0.30	$ 1
Fair Value Assumptions, Expected Term	5 years	2 years
Fair Value Assumptions, Expected Volatility Rate	219.00%	302.00%
Fair Value Assumptions, Risk Free Interest Rate	1.57%	0.63%
Maximum | Fair Value, Inputs, Level 3
Fair Value Assumptions, Exercise Price	$ 0
Fair Value Assumptions, Expected Term	6 years 4 months 24 days
Fair Value Assumptions, Expected Volatility Rate	189.00%
Fair Value Assumptions, Risk Free Interest Rate	1.44%
Fair Value Assumptions Common Stock Price	$ 0.40

16. Common Stock Options and 94

16. Common Stock Options and Warrants: Schedule of Share-based Compensation, Activity (Details) - $ / shares	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Details
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	32,520,037	9,497,551
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.13	$ 0.91
Share-based compensation arrangement by share-based payment award, Options, Grants in period	28,882,780
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.07
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	(326,200)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	$ 0.81
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period	(5,534,097)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price	$ 1.10
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	28,015,034
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 0.11

16. Common Stock Options and 95

16. Common Stock Options and Warrants (Details)	Sep. 30, 2016USD ($)
Details
Aggregate Intrinsic Value	$ 0
Weighted average remaining term of the warrants	5

17. Segment Information_ Sche96

17. Segment Information: Schedule of Segment Reporting Information, by Segment (Details) - USD ($)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Chronic illness monitoring supplies revenues	$ 6,327,832	$ 5,994,793
Net loss	(9,122,560)	(11,527,669)
Interest expense, net	(2,963,747)	(977,234)
Total assets	1,618,206	2,538,960
Corporate Segment
Net loss	(10,151,704)	(10,757,547)
Interest expense, net	2,963,747	977,234
Total assets	926,469	767,302
Payments to Acquire Property, Plant, and Equipment	5,004	15,289
Depreciation, Depletion and Amortization, Nonproduction	51,376	57,036
Chronic Illness Monitoring
Chronic illness monitoring supplies revenues	7,464,146	6,597,981
Net loss	1,029,144	(583,890)
Total assets	691,737	1,771,658
CareServices
Chronic illness monitoring supplies revenues		152,686
Net loss		(186,232)
Depreciation, Depletion and Amortization, Nonproduction		233,664
Total
Chronic illness monitoring supplies revenues	7,464,146	6,750,667
Net loss	(9,122,560)	(11,527,669)
Interest expense, net	2,963,747	977,234
Total assets	1,618,206	2,538,960
Payments to Acquire Property, Plant, and Equipment	5,004	15,289
Depreciation, Depletion and Amortization, Nonproduction	$ 51,376	$ 290,700

18. Income Taxes (Details)

18. Income Taxes (Details)	Sep. 30, 2016USD ($)
Details
Operating Loss Carryforwards	$ 89,295,000

18. Income Taxes_ Schedule of98

18. Income Taxes: Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Details
Deferred Tax Assets, Operating Loss Carryforwards	$ 33,307,000	$ 29,000,000
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals	442,000	721,000
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits	1,619,000	1,728,000
Deferred Tax Assets, Tax Deferred Expense, Other	23,000	28,000
Deferred Tax Assets, Valuation Allowance	$ (35,391,000)	$ (31,477,000)

18. Income Taxes_ Schedule of99

18. Income Taxes: Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Details
Current Federal Tax Expense (Benefit)	$ 3,102,000	$ 3,919,000
Current State and Local Tax Expense (Benefit)	300,000	380,000
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount	498,000	(367,000)
Other Tax Expense (Benefit)	14,000	112,000
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount	$ (3,914,000)	$ (4,044,000)

19. Commitments and Continge100

19. Commitments and Contingencies (Details) - USD ($)	9 Months Ended	12 Months Ended
	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Details
Operating Leases, Rent Expense, Net	$ 226,000	$ 126,000	$ 31,000

19. Commitments and Continge101

19. Commitments and Contingencies: Schedule of Future Minimum Rental Payments for Operating Leases (Details)	Sep. 30, 2016USD ($)
Details
Operating Leases, Future Minimum Payments Due, Next Twelve Months	$ 130,036
Operating Leases, Future Minimum Payments, Due in Two Years	111,340
Operating Leases, Future Minimum Payments Due	$ 241,376

20. Related Party Transactio102

20. Related Party Transactions Not Otherwise Disclosed (Details) - USD ($)	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Issuance of common stock for consulting services	$ 235,100	$ 645,000
PurizerCorporationMember
Stock Issued During Period, Shares, Issued for Services	250,000
Issuance of common stock for consulting services	$ 53,500
AdpManagementMember
Other Cost of Services	$ 6,000
MrJeffreyPetersonMember
Stock Issued During Period, Shares, Issued for Services	2,000,000
Issuance of common stock for consulting services	$ 360,000
Other Cost of Services	$ 20,000